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I certify that this thesis is an original piece of work. Chapters 1 and 2 are a review of the physiology 
of cervical ripening and the induction of labour. Before writing these chapters I conducted a 
literature search. In chapter 3 the results of a study examining the maternal and fetal haemodynamic 
effects following the intra-vaginal administration of isosorbide mononitrate are presented. In this 
study 1 recruited and consented all patients, collected all data and performed analysis of the data. The 
role of others in this study is referred to in the text.
Antony Edward Nicoll.
Abstract:
The ideal agents for the induction of labour should be clinically effective, easy to administer, cost- 
effective and safe for both mother and fetus. Mechanical devices, oestrogens, progesterone 
antagonists, relaxin, and prostaglandins have all been used to induce cervical ripening, with varying 
rates of efficacy and adverse effects. The intra-vaginal administration of the nitric oxide donor 
isosorbide mononitrate (IMN) is effective at inducing cervical ripening in the first trimester of 
pregnancy. When used to induce cervical ripening in the first trimester, intra-vaginal IMN also has 
fewer adverse effects than intra-vaginal prostaglandins. Nitric oxide is a potent vasodilator. The 
effects of intra-vaginal IMN on maternal and fetal haemodynamics in pregnant women at term are 
not known.
The first two chapters of this thesis provide a review of the physiology of parturition and of the agents 
that can be used to artificially induce cervical ripening. The final part of this thesis will present the 
results of a study of the maternal and fetal haemodynamic effects of intra-vaginal IMN administered 
to pregnant women at term.
Study Design:
A double blind randomised controlled trial. 36 women were randomised to receive 20 milligrams 
intra-vaginal IMN (n=I3), 40 milligrams intra-vaginal IMN (n= ll), or no treatment (a vaginal 
examination only) (n=12). Maternal pulse, blood pressure and fetal heart rate were recorded before 
the administration of any treatment and subsequently at 30-minute intervals until 360 minutes. 
Umbilical artery resistance index and pulsatility index measurements were made at 0, 180 and 330 
minutes. Participating women were asked to complete a symptom questionnaire immediately before 
the administration of the treatment and again at 360 minutes. On completion of the study cervical 
score was determined, and if  required further cervical ripening was achieved with prostaglandins in 
accordance with the local protocol. Other outcome measures included mode of delivery, length of 
labour for those women who progressed to a vaginal delivery, volume of blood loss at delivery, 
umbilical cord pH, Apgar scores at 1 and 5 minutes, analgesic requirements in labour and whether or 
not infants required admission to the neonatal unit.
Results:
Mean maternal pulse rate was greater following the intra-vaginal administration of 20 and 40 
milligrams IMN compared with the control group (p = 0.003 and p = 0.01 respectively). Mean 
maternal systolic and diastolic blood pressures were lower following the intra-vaginal administration 
of 40 milligrams IMN compared with the control group (p = 0.006 and p = 0.001). Mean maternal 
diastolic blood pressure was lower following the intra-vaginal administration of 20 milligrams IMN 
compared to the control group (p = 0.01). Neither dose of IMN had a significant effect on mean fetal 
heart rate and umbilical artery resistance or pulsatility index. 69% and 91% of participants reported 
a headache following the administration of 20 mg and 40 mg IMN respectively, compared to 8% of 
the control group (p = 0.001). None of the study participants required treatment for maternal 
hypotension, or maternal or fetal tachycardia. The numbers were too small to demonstrate any 
statistically significant change in cervical score and there were no statistically significant differences 
in other outcome measures.
Conclusion:
The intra-vaginal administration of 20 mg and 40mg IMN to pregnant women at term has an effect 
on maternal haemodynamics, but this effect does not appear to be of clinical significance. In this 
study no effect on fetal haemodynamics was demonstrated following the intra-vaginal administration 
of 20 mg and 40mg IMN to pregnant women at term. This thesis lays the foundation for fiirther 
studies using IMN as a cervical ripening agent during the induction of labour in pregnant women at 
term.
Introduction;
Despite advances in our understanding of the cellular and biochemical events that occur during 
parturition, the search for the factors that initiate and regulate this complex process continues. There 
are many reasons why a greater knowledge of this process would be beneficial. In circumstances 
where the continuation of pregnancy presents a risk to the mother or the fetus, for example in severe 
preeclampsia or intra-uterine growth restriction, an ability to folly comprehend the events of 
parturition could lead to the development of more physiological, and therefore safer, methods for the 
artificial induction of labour. A greater awareness of the events of parturition could provide us with 
the means to help those women who experience dysfunctional labour.
In addition, pre-term labour affects up to 10% of all pregnancies and is the major cause of neonatal 
mortality and morbidity. In recent years neonatal survival following pre-term delivery has greatly 
improved, although not through advances in obstetric intervention K A better understanding of the 
physiology of parturition could also help us to overcome this continuing problem.
Human parturition consists of two distinct phases The first phase occurs during the final weeks of 
pregnancy and involves re-modelling of cervical connective tissue. This preparatory phase of 
parturition is known as cervical ripening. The second phase of parturition is much shorter than the 
first and lasts for hours. This phase is knovm as active labour and consists of regular uterine activity 
with progressive dilation of the cervix and leads to delivery of the infant. By considering human 
parturition in this way, strategies have developed for the artificial induction of labour. A frequently 
used method involves the induction of the first phase of parturition with a cervical ripening agent, 
followed by amniotomy and infusion of oxytocin to initiate the second phase.
The ideal agents for the induction of labour should be clinically effective, easy to administer, cost- 
effective and be safe for both the mother and fetus. Many agents have been used to induce cervical 
ripening including mechanical devices, oestrogens, progesterone antagonists, relaxin, and 
prostaglandins. These agents all vary in effectiveness and have a wide spectrum of adverse features.
It is now apparent that nitric oxide (NO) is a crucial factor in the process of cervical connective tissue 
remodelling during parturition in both animals and humans Consequently, NO donors such as 
isosorbide mononitrate have been proposed as suitable agents for the pharmacological induction of 
cervical ripening in pregnant women Our experience of using NO donors in pregnant
women at term is limited. There have been no studies examining the maternal and fetal
haemodynamic effects of NO donors administered intra-vaginally to pregnant women at term for the 
induction of cervical ripening.
This thesis will first attempt to summarise the histological and biochemical changes of cervical
ripening and the factors that regulate this process. There will subsequently be a review of the
methods that have been used in clinical practice to artificially induce cervical ripening. Finally the 
results of a study will be presented, in which the NO donor isosorbide mononitrate was administered 
to pregnant women at term, in order to examine the effects on maternal and fetal haemodynamics. 
This study will hopefiilly lay the foundation for a future randomised controlled trial of NO donors, 
administered intra-vaginally to pregnant women at term, for the induction of cervical ripening.
I. The Physiology of Cervical Ripening:
The cervix is a unique structure in the female reproductive system and has many important fonctions. 
Outside pregnancy the cervix is a two-way channel enabling the passage of sperm into the upper part 
of the female reproductive tract in one direction, and the flow of menses in the other. The cervix has 
important immunological fonctions; the mucus produced by the glandular elements within the cervix 
is a barrier to pathogens and also sperm. Throughout pregnancy the cervix continues to act as a 
barrier to pathogens, but must also keep the fetus inside the uterus. During parturition the cervix 
undertakes a new role and must progressively soften, efface and dilate, to facilitate the passage of the 
fetus through to the outside world.
Anatomy of the Cervix:
The cervix is the inferior part of the uterus that protrudes into the vagina. It is situated between the 
bladder, which is located anteriorly, and the rectum, which lies posteriorly. The pubo-cervical fascia, 
the utero-sacral ligaments and the cardinal ligaments support the cervix. The cervix is cylindrical in 
shape and is approximately 2 - 3  centimetres long and 0 . 5 - 1  centimetre wide. In pre-pubescent 
females the cervix is twice as long as the uterine corpus, whilst in nulliparous females the cervix and 
the uterine body are approximately equal in length. In multiparous women the uterine corpus is 
approximately twice as long as the cervix
The endocervical canal runs through the entire length of the Cervix. The superior opening of the 
canal is located at the level of the peritoneal reflection of the bladder and is known as the internal os. 
The canal ends at the inferior opening, the external os. The endocervical canal is lined by tall 
columnar epithelial cells, which are interspersed with glands. These glandular epithelial cells end 
abruptly at the external os. The glandular epithelium is replaced by non-keratinised stratified 
squamous epithelium that is continuous with the epithelium of the vagina. The epithelial junction is 
referred to as the transformation zone.
In contrast to the uterine corpus, the cervix predominantly consists of connective tissue and only 15% 
of the cervix consists of smooth muscle While some of the deeper muscle fibres within the cervix 
may function as contractile elements " , the significance of endocervical submucosal smooth muscle 
found in some women remains unclear and may represent a variation of normal
The extra-cellular matrix of the cervix is rich in type I (~ 80%) and type III (~ 20%) collagen 
There is also a small amount of type IV collagen present in the basement membranes of the epithelial 
elements. Collagen fibres are synthesised from tropocollagens, which are bound together by covalent 
cross-links. These cross-links are important for collagen stability; mature collagen has more stable 
cross-links and is thus more resistant to degradation. In the cervix of non-pregnant females collagen 
fibres have a cable-like structure and are organised into dense bundles. The collagen fibres are held 
together by a relatively small amount of ground substance.
The ground substance mainly consists of large proteoglycan complexes that contain one or more 
glycosaminoglycans (GAGs) connected to a protein core. GAGs, formerly knovm as acid 
mucopolysaccharides, are large unbranched polysaccharide chains. They consist of disaccharide 
repeating units that contain a hexosamine (glucosamine or galactosamine) residue and mostly an 
uronic acid (glucuronic acid or iduronic acid) residue GAGs frequently contain a high amount of 
sulphate groups, making them extremely hydrophilic. Examples of GAGs include keratan sulphate, 
heparan sulphate and hyaluronic acid. In the cervix the main GAGs are condroitin sulphate and its 
epimer dermatan sulphate
There are at least three types of proteoglycan PG-Sl (biglycan) is a small proteoglycan with two 
dermatan sulphate chains, while PG-S2 (decorin) is also small but has only one dermatan sulphate 
chain. PG-L (chondroitin) is a large proteoglcan with both chondroitin and dermatan sulphate side 
chains. In the non-pregnant cervix PG-S2 is dominant
The close association of the proteoglycan complexes and collagen fibres is crucial for the alignment of 
the collagen fibres. It is this relationship that provides the cervix with its tensile strength. The 
various GAGs vary in chain length and charge density and hence, in their ability to bind collagen.
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For example, dermatan sulphate has a strong affinity for collagen and will therefore increase tissue 
rigidity. Hyaluronic acid has a high affinity for water molecules and binds least strongly to collagen 
and acts to destabilise the collagen fibres. Changes in proteoglycan and GAG composition will 
therefore have profound effects on the stability of collagen binding.
A small amount of elastin is also found within the cervical stroma Elastin fibres maintain the 
shape of the cervix and play a major role in keeping the cervix closed The function of elastin fibres 
assumes greater importance during pregnancy and indeed the “incompetent” cervix, which is 
associated with pre-term labour, has reduced amounts of elastin Elastin may also assist the cervix 
in returning to its pre-pregnant shape after delivery. Fibronectin and water are also found within the 
cervical extracellular matrix
The composition of the cervical stroma is determined by fibroblasts, which synthesise and degrade the 
major extracellular matrix elements.
The Cervix During Pregnancy and Cervical Ripening:
During pregnancy there are profound changes in the composition of the cervix, which are most 
marked immediately before and during labour. There is an increase in cervical water content fi’om 80 
to 86% which appears to be the result of an increase in hydrophilic GAGs In comparison to the 
non-pregnant cervix, there is a 30% reduction in cervical collagen concentration at 10 weeks 
gestation, and a 70% reduction at term There are also qualitative changes in cervical collagen. At 
term the collagen fibres appear thinner and are more widely spread out Cervical collagen fibres 
also decrease in fibre length Collagen synthesis continues throughout pregnancy, but the 
immature collagen does not develop strong cross-links with other collagen fibres. Consequently this 
newly formed collagen is more susceptible to degradation
Matrix metalloproteinases (MMPs) are enzymes that are essential for connective tissue remodelling. 
At least 17 MMPs have been identified in humans. Collagen is resistant to most extracellular 
proteinases except collagenase (MMP-I) and leukocyte elastase MMP-1 is specific for collagen
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and is secreted by a number of cells including fibroblasts and cleaves collagen at a specific site. 
MMP-1 is secreted as a pro-enzyme and is activated extra-cellularly by stromelysin (MMP-3). MMP- 
3 is activated by a number of enzymes including elastase MMP-3 is therefore essential for full 
collagenase activity. MMP-9 (type IV collagenase-gelatinase B) is also important in cervical collagen 
degradation, and activation of MMP-9 is dependent upon activating protein-1 (AP-1) There are 4 
inhibitors of MMP activity: tissue inhibitor of metalloproteinase 1 - 4  (TIMP-1, TIMP-2, TIMP-3 
and TIMP-4).
In the cervix there is active breakdown of collagen fibres during pregnancy. Cervical MMP-1 activity 
is increased during pregnancy and MMP-1 activity is maximal immediately before the onset of 
parturition During parturition neutrophilic polymorphonuclear leukocytess are the main source 
of MMP-1 In the rat cervix, MMP-9 expression is increased in response to agents that have been 
shown to promote cervical ripening Leukocyte elastase degrades many proteins, including 
collagen, elastin and proteoglycans. Leukocyte elastase activity also increases throughout pregnancy
At term the total proteoglycan concentration is halved and there is an increase in the amounts of PG- 
Sl and PG-L in comparison to PG-S2 PG-Sl and PG-L bind less strongly to collagen fibres
than PG-S2. In rats cervical ripening is associated with an increase in the ratio of PG-S2 to collagen 
The interaction of PG-S2 and collagen in the cervix at term appears to be an important factor in 
destabilising collagen fibres, resulting in a loss of tensile strength^^.
There also appears to be a qualitative change in the cervical GAG composition, with an increase in 
keratan sulphate during pregnancy. Chondroitin and dermatan sulphate concentrations decrease 
During pregnancy cervical hyaluronic acid content may remain unchanged or may decrease 
However, it is now apparent that cervical hyaluronic acid levels remain low during pregnancy and 
increase with the onset of parturition Hyaluronic acid stimulates MMP production in the rabbit 
cervix and stimulates neutrophil chemotaxis Hyaluronic acid also stimulates collagenase and 
gelatinase activity in the human lower uterine segment and may also do so in the cervix Changes
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in proteoglycan and GAG composition of the cervix during pregnancy and labour alter the ground 
substance to which the collagen fibres are embedded and serve to destabilise the collagen.
During pregnancy there is also an eight-fold increase in the concentration of cervical elastin, which 
decreases rapidly after parturition The elastin fibres in the cervix of pregnancy are arranged in a 
characteristic fishnet appearance
Throughout pregnancy the cervix is infiltrated by leukocytes In early pregnancy these are mainly 
T lymphocytes, with a small number of neutrophilic polymorphonuclear leukocytes present, along 
with a very small number of macrophages. At term there is a marked increase in the number of 
neutrophilic and eosinophilic polymorphonuclear leukocytes within the cervix and these cells are 
often surrounded by a halo of tissue that has reduced collagen content At term there is also a 10- 
fold increase in the number of macrophages compared to early pregnancy
There also appears to be an increase in programmed cell death (apoptosis) of cervical smooth muscle 
cells at term and this may be an important factor in the initiation of cervical ripening
In early pregnancy collagen and elastin fibres, along with fibroblasts and smooth muscle cells, align 
parallel to one another This arrangement assists in the maintenance of pregnancy. By term the 
changes in the composition of the cervical stroma lead to a structural derangement of the extracellular 
matrix elements, and hence a reduction in cervical rigidity. The cervical connective tissue changes 
are manifest clinically as progressive softening, shortening and dilatation of the cervix, with an 
associated change in cervical position. The “ripeness” of the cervix can be measured using the 
modified Bishop Score and this score is a good indicator of the preparedness of the cervix for 
parturition
Cervical Ripening as an Inflammatory Reaction:
The physiological changes in the cervix during cervical ripening resemble those of the inflammatory 
reaction Following any tissue insult there is local vasodilatation that is associated with an increase
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in blood flow. This is followed by an increase in vascular permeability and the exudation of proteins 
and fluid into the interstitial tissues. Oedema and fibrin deposits are seen in the interstitial spaces. 
The next stage in the inflammatory process is the adhesion of leukocytes to the vessel walls and their 
subsequent migration in response to chemotactic agents. The migrating cells initially consist of 
neutrophil polymorphs and are followed by macrophages and, later, eosinophils.
After the destructive phase of inflammation a rebuilding and re-modelling phase occurs. Fibroblasts 
proliferate and migrate into the tissues and synthesise collagen, proteoglycans and GAGs. The main 
GAG secreted during the inflammatory process is hyaluronic acid. Fibroblasts are also a source of 
prostaglandins and proteolytic enzymes. The synthesis of new connective tissue is associated with 
increased tissue degradation. The whole inflammatory reaction is controlled by a number of factors 
including cytokines, histamine and prostaglandins.
There are several similarities between the inflammatory reaction and the process of cervical ripening. 
As previously discussed, during cervical ripening there is an increase in tissue hydration and an 
alteration of the cervical extra-cellular matrix, with both qualitative and quantitative changes in 
collagen and proteoglycan composition. During cervical ripening there is also an influx of leukocytic 
cells. Many of the mediators and enzymes involved in the regulation of the acute inflammatory 
reaction are also involved in the regulation of cervical ripening.
The Regulation of Cervical Ripening:
Inflammation may be triggered by trauma, chemical agents, infective agents, or be part of a 
hypersensitivity reaction. The process of cervical ripening also appears to have many possible 
triggers. While it is recognised that some cases of pre-term labour are the result of an infective 
trigger one must assume that in the healthy woman at term, other factors must be involved in the 
initiation of parturition.
As previously discussed, human parturition has two phases that are closely related, cervical ripening 
and active labour. In normal parturition cervical ripening must occur before active labour. Parturition
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begins when the forces that fevour cervical ripening and active labour overcome those that prevent 
these processes. Important factors in the regulation of parturition include cytokines, mechanical 
stress, apoptosis of cervical cells, endocrine factors (placental corticotrophin releasing hormone, 
progesterone, oestrogen, and oxytocin), relaxin, prostaglandins and nitric oxide.
Cytokines:
The inflammatory process is regulated by a diverse group of soluble proteins and polypeptides known 
as cytokines. Cytokines regulate cellular function in both normal and pathophysiological conditions. 
Cytokines usually contain between 100 and 200 amino acid residues and have a molecular weight of 
10-20 kilodaltons. Cytokine function is mediated by their binding to specific membrane associated 
receptors Since cervical ripening is similar to the inflammatory process, this would suggest that 
cytokines play a role in the regulation of cervical connective tissue re-modelling during parturition.
The principal groups of cytokines are: interleukins (1-18); the interferons a, p and y; colony 
stimulating factors (G-CSF, M-CSF and GM-CSF); tumour necrosis factors a  and P; the transforming 
growth foctor P family; and additional growth factors such as erythropoietin, nerve growth factor, 
epidermal growth factor, fibroblast growth factors, insulin-like growth factors and platelet derived 
growth factor The cytokines involved in the regulation of inflammation are the interleukins, TNF- 
a  and -p, platelet activating factor (PAF) and the interferons.
Interleukin-la and interleukin-ip are 17kD peptides that are synthesised by many cells, including 
fibroblasts, endothelial cells, monocytes and macrophages. IL -la and IL-ip have similar biological 
effects and are recognised by the same receptors. They are pro-inflammatory and stimulate the 
production of IL-6, IL-8 and TNF IL -la and IL-ip are important mediators of parturition. 
Amniotic fluid IL -la concentrations increase in term labour
IL -la and IL-ip regulate cervical ripening by altering the activities of MMPs and by altering cervical 
GAG composition. IL -la  induces the expression of MMP-1 and MMP-3, down-regulates the 
expression of TIMPs and inhibits matrix synthesis IL-lp also induces MMP-1, -3, and -9 mRNA
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expression in cultured human cervical smooth muscle cells in vitro, along with the elastinolytic 
enzyme cathepsin S The effects of lL-1 on MMP production are mediated by protein kinase C 
IL-la stimulates fibroblast hyaluronic acid production
Interleukin-8 is a small (6-8kD) peptide produced by monocytes, fibroblasts and chorio-decidual cells 
IL-1, TNF and aminopeptidase inhibitor (bestatin) regulate the production of IL-8
IL-8 is a crucial factor in the regulation of cervical ripening Cervical fibroblasts have the capacity 
to produce IL-8 in large amounts during pregnancy Pre-term labour is associated with increased 
concentrations of amniotic fluid IL-8 and it has been suggested that the measurement of IL-8 in 
cervical secretions may be a usefiil marker for pre-term labour During parturition the production 
of lL-8 within the cervix is dependent on IL -la
IL-8 is a powerfiil neutrophil chemotactic agent, promotes neutrophil activation and also increases 
vascular permeability Thus IL-8 could account for the influx of neutrophilic polymorphonuclear 
leukocytes that is seen during cervical ripening. There is also evidence to suggest that IL-8 can 
influence cervical MMP activity during parturition and also alter GAG composition. IL-8 stimulates 
MMP-8 and MMP-9 release from neutrophils and stimulates fibroblast hyaluronic acid production 
in vitro
Tumour Necrosis Factor (TNF) is a 17kD peptide and is released from monocytes and macrophages. 
TNF appears to be another factor in the regulation of cervical ripening. TNF regulates the activities 
of other inflammatory cytokines including IL-I, IL-6, IL-8 and interferon, as well as phospholipase 
A2, PAF and protein kinase C TNF-a also alters cervical connective tissue composition by
stimulating the production of MMPs TNF-a induces MMP-1, -3, and -9 mRNA expression in 
cultured human cervical smooth muscle cells in vitro, along with the elastinolytic enzyme cathepsin S
Transforming growth factor can also increase MMP production and this cytokine may also be an 
important factor in the regulation of cervical ripening, although fiirther investigation is required.
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Mechanical Factors;
Cervical ripening is an active process. However the pressure effects exerted passively on the cervix 
by the fetus undoubtedly play a role in stimulating the connective tissue changes of cervical ripening. 
Treatment of rats with the progesterone antagonist mifepristone induces qualitative changes in 
cervical collagen content but not foil cervical ripening In this study Glassman et al concluded that 
the mechanical distension of the cervix caused by the fetus was essential for complete ripening to 
occur
El Maradny et al demonstrated that stretching of fetal membranes and also myométrial cells from the 
lower uterine segment results in an increase in IL-8 concentration and collagenase activity in vitro 
It appears logical to suggest that passive mechanical stretching of the fetal membranes, the lower 
uterine segment and the cervix, by the fetal presenting part could promote the release of IL-8 and 
hence other pro-inflammatory cytokines, and promote the cervical connective tissue remodelling at 
term in vivo. It would be of interest to repeat the study of El Maradny et al using cervical tissue in 
order to determine whether or not stretching of cervical tissue also induces IL-8 and collagenase 
production.
The mechanical stress caused by myométrial activity may also be involved in the initiation of cervical 
ripening Myométrial contractions will cause sheer stress on the cervical tissues, promoting 
inflammatory changes within the cervix. Inflammatory mediators such as IL-1, IL-6 and TNF 
increase prostaglandin production in a variety of animal and human cells in vitro Prostaglandins 
will further promote myométrial contractility. It therefore appears that a positive loop is set up to 
drive forward the process of parturition once cervical ripening has been initiated.
Apoptosis:
The length of pregnancy is relatively constant within a species group and the idea of genetically 
determined cell death triggering parturition is appealing. In rats there is an increase in apoptosis of
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cervical smooth muscle cells at term It has been suggested that apoptosis of cervical smooth 
muscle cells could be a factor in the initiation of human cervical ripening
Apoptosis is regulated by cytokine and endocrine factors, including TNF-a and glucocorticoids 
The administration of the progesterone antagonist onapristone inhibits apoptosis of smooth muscle 
cells and fibroblasts in the cervices of pregnant rats An increase in smooth muscle cell apoptosis 
in the cervix at term may simply be a response to other events in the parturition process, rather than 
an initiating factor. Further work is required to determine the exact role of apoptosis in the 
regulation of human cervical ripening.
Placental Corticotrophin Releasing Hormone:
In humans corticotrophin releasing hormone (CRH) is released from the hypothalamus and is a major 
factor in the hypothalamic-pituitary-adrenal axis. CRH is released in response to stress and 
stimulates adrenocorticotrophin (ACTH) release from the anterior pituitary gland. ACTH stimulates 
glucocorticoid release from the adrenal glands. A negative feedback loop exists, whereby 
glucocorticoids inhibit both CRH and ACTH release at the hypothalamus and pituitary gland.
CRH has been identified in the human placenta Placental CRH is a peptide with identical size 
and biological activity to hypothalamic CRH, and is synthesised in syncytiotrophoblast cells CRH 
receptors have been found in the myometrium and placental CRH can stimulate myométrial activity 
Placental CRH synthesis is increased in the last 6-8 weeks of human pregnancy and high levels of 
placental CRH are associated with pre-term labour, pregnancy induced hypertension and intra-uterine 
growth restriction
Hypothalamic CRH release is mediated by IL-I and TNFa and is dependent upon nitric oxide 
production The link between inflammatory cytokines and CRH production probably also
exists in the female reproductive tract In vitro experiments have shown that IL-1 and 
prostaglandins promote the production of placental CRH Progesterone may inhibit placental CRH
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synthesis via its action on trophoblast glucocorticoid receptors In contrast to their inhibitory 
effects on hypothalamic CRH, glucocoticoids promote placental CRH gene expression
In humans there is a rise in fetal cortisol production at term Fetal cortisol promotes fetal lung 
maturation, an important step in the preparation for delivery. Placental CRH stimulates the release of 
fetal ACTH from the fetal pituitary gland, which in turn stimulates further production of fetal cortisol 
from the fetal adrenal cortex. A positive “feed-forward” loop is established ensuring a rise in 
placental CRH.
Fetal ACTH also stimulates the production of düiydroepiandrosterone (DHEA) in the fetal adrenal 
gland. Increases in plasma DHEA concentrations are associated with cervical ripening DHEA 
appears to act synergistically with IL-8 in the process of cervical ripening, and acts by increasing 
MMP and elastase activities In the placenta DHEA is converted to oestradiol. Oestradiol
increases myométrial gap junction formation, increases the number of myométrial oxytocin receptors, 
and stimulates prostaglandin formation These changes will promote myométrial contractility, 
which further stimulates the process of cervical ripening.
The trigger for the rise in fetal cortisol production is unknown. The hypothalamic-pituitary-adrenal 
axis is activated in response to stress. An increase in fetal cortisol production could be a 
physiological reaction to a stressful event, such as infection or hypoxia. The placenta may not be 
meeting the demands of the fetus either through disease or because the fetus has out-grown its 
supplier. There may be a biological clock functioning within the fetal hypothalamus or the placenta 
(or both), which upon activation increases CRH production and thus triggers parturition.
Oestrogen:
In animals, including the sheep and the rat, plasma levels of oestrogen rise and progesterone levels 
fall immediately before the onset of parturition In humans there does not appear to be a fall in 
plasma levels of progesterone, but an alteration in the ratio of plasma oestradiol to progesterone 
during the later stages of pregnancy and during parturition has been reported Women who
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progress to spontaneous labour have a higher ratio of salivary oestrogen to salivary progesterone 
concentration than those women who do not labour spontaneously Furthermore, a raised salivary 
oestriol concentration may be a marker for pre-term labour Cervical ripening is associated with 
raised plasma 17p-oestradiol
As discussed previously, in humans the shift from progesterone to oestrogen dominance at term is 
dependent on the activation of the fetal hypothalamic-pituitary-adrenal axis, and the placental 
conversion of DHEA to oestradiol An increase in oestrogen activity will have effects at the 
myométrial and cervical levels. In the myometrium oestrogens increase myométrial gap junction 
formation, oxytocin receptor synthesis, and prostaglandin synthesis These changes promote 
myométrial contractility.
In human cervix at term there is a reduction in cervical oestrogen and progesterone receptor protein, 
compared to non-pregnant controls, that is the result of an increase in receptor turnover Insulin­
like growth fector-1 is a mediator for growth hormone that has also been proposed as a mediator for 
oestrogen action in the uterus The changes demonstrated by Stjernholm et al in the human cervix 
at term were associated with a four-fold rise in cervical IGF-1 mRNA which suggests that oestrogen 
activity is present in the cervix at the time of parturition. A subsequent study showed a further 
decrease in oestrogen and progesterone receptor protein and IGF-1 mRNA concentrations occurred 
dming parturition This implies that oestrogen activity is less important for cervical connective 
tissue remodelling once parturition is initiated.
Animal and human studies demonstrate that the oestrogens have a variety of effects on cervical 
connective tissue. In pregnant rats administration of oestradiol at term leads to a reduction in both 
the total and the soluble collagen content In the same study the administration of tamoxifen, an 
oestrogen antagonist with partial agonist activity, did not affect total cervical collagen content, but did 
reduce the amount of soluble cervical collagen In humans the administration of oestradiol reduces 
the total cervical collagen content and increases the amount of soluble collagen
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Oestrogens may alter cervical composition and fecilitate cervical ripening by stimulating MMP 
activity. In guinea pigs 17p-oestradiol stimulates cervical MMP activity in vitro Oestrone 
sulphate increases MMP activity in cervical tissue taken from women at term in vitro However 
Sato et al demonstrated that 17p-oestradiol reduces MMP activity and increases TIMP production in 
the rat cervix in vitro Oestrogen replacement alone in pregnant rats at term following 
oophorectomy produces a compact and inextensible cervix, whereas the administration of oestrogen 
and relaxin produced changes that were similar to those of cervical ripening It may be that at 
physiological concentrations oestrogens do not directly exert much influence on MMP production, 
and hence MMP activity, and that other agents in the ripening cascade are more important in the 
regulation of cervical collagen content.
It appears likely that oestrogens influence cervical ripening through processes other than the direct 
alteration of cervical collagen composition. Oestrogens can induce apoptosis  ^ and also promote 
cervical eosinophilic infiltration in pregnant rats at term Oestrogens also regulate the binding of 
relaxin, another mediator of cervical ripening, to porcine cervical cells It may be that the effects of 
oestrogen on the cervix are indirect and are mediated by prostaglandins, myométrial activity, or via 
relaxin. Further work is required to determine the exact mechanisms by which oestrogens regulate 
cervical ripening.
Progesterone;
In animals there is a shift from progesterone to oestrogen dominance at term and this change is 
believed to be a crucial factor in determining the timing of the onset of parturition In sheep
fetal cortisol stimulates the production of I7a-hydroxyprogesterone lyase, an enzyme that is 
responsible for progesterone breakdown. The human placenta does not contain 17 a- 
hydroxyprogesterone lyase, and so a rise in fetal cortisol will not lead to a reduction in progesterone. 
However fetal cortisol may displace progesterone from glucocorticoid receptors in the myometrium 
and cervix, thereby simulating progesterone ’’withdrawal”
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It has long been recognised that progesterone inhibits cervical ripening Antagonists to 
progesterone such as mifepristone (RU 486), induce cervical ripening in both animals and humans 
90, 91,92 rat cervices the administration of a progesterone antagonist is associated with a decrease 
in the amount of mature cross-linked collagen, an increase in the amount of soluble cervical collagen, 
but a decrease in cervical hydration The administration of the progesterone antagonist
onapristone also increases the PG-S2 (decorin) / collagen ratio and alters cervical extensibility of the 
pregnant rat cervix
In humans mifepristone induces cervical softening and dilatation in vivo, and inhibits cervical 
collagen synthesis in vitro but does not alter the total amount of cervical collagen In the human 
cervix there is a reduction in progesterone receptor at term and during parturition that is associated 
with cervical connective tissue remodelling
Progesterone appears to regulate cervical ripening by inhibiting cervical collagen breakdown 
Progesterone inhibits the lL-1 induced production of MMP-1, MMP-3, and MMP-9, and augments 
IL-1 induced production of TIMP-1 and TIMP-2 from rabbit cervical fibroblasts in vitro It is
likely that mifepristone promotes cervical ripening by inducing collagen fragmentation and 
breakdown and this effect may be mediated by prostaglandins
Endothelial adhesion molecules are crucial for the adhesion of leukocytes to the vascular endothelium 
prior to chemotaxis, a crucial part of the process of cervical ripening. Whilst progesterone alone does 
not appear to affect the expression of these endothelial adhesion molecules in umbilical vein 
endothelial cells in vitro the progesterone antagonist onapristone increases the expression of the 
endothelial adhesion molecule endothelial leukocyte adhesion molecule-1 (ELAM-1) in umbilical 
vein endothelial cells in vitro The combination of onapristone and TNFa led to increased 
expression of ELAM-1, along with expression of intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1). These effects are also seen when 17p oestradiol is used 
rather than onapristone
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Progesterone antagonists also increase the production of IL-8 in the human placenta resulting in 
neutrophil polymorph chemotaxis and activation Hypothetically the same events could occur in 
the cervix during cervical ripening, in response to progesterone “withdrawal” . There is also evidence 
to suggest that progesterone is an inhibitor of apoptosis. Progesterone inhibits the 
aminoglutethamide-induced apoptosis of bovine corpus luteal cells in vitro, whilst the progesterone 
antagonists, mifepristone and onapristone, increased apoptotic cell death Conversely Leppert et al 
demonstrated that the administration of the progesterone antagonist onapristone inhibited apoptosis 
of smooth muscle cells and fibroblasts in the cervices of pregnant rats
Therefore, during pregnancy progesterone inhibits the degradation of the cervical collagen and hence 
conserves the tensile strength of the cervix. At term there appears to be a “withdrawal” of 
progesterone activity likely to be the result of progesterone receptor antagonism by fetal cortisol 
The suppression of MMPs and induction of TIMPs by progesterone is lost and there is an influx of 
inflammatory cells into the cervix. It is again likely that the “withdrawal” of progesterone activity 
only partially influences cervical ripening, and that it is one of many factors that regulate cervical 
ripening.
Oxytocin:
The presence of oxytocin is critical for the initiation and maintenance of parturition. Oxytocin is a 
short polypeptide with a molecular weight of 1000 Oxytocin, along with vasopressin, is released 
from the posterior lobe of the pituitary gland. Oxytocin is synthesised in the paraventricular and 
supraoptic nuclei by the formation of large precursor molecules that are cleaved and stored in the 
neurohypophysis. Oxytocin and vasopressin have similar structures and differ only by the substitution 
of 2 amino acid residues.
Oxytocin is released in a pulsatile manner fr-om the neurohypophysis in response to a number of 
stimuli including breast stimulation, sensory stimuli from the lower genital tract, and cervical 
stretching The release of oxytocin following breast stimulation results in oxytocin-induced 
contraction of mammaiy myoepithelial cells, the milk-ejection reflex Vaginal and cervical
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stretching leads to oxytocin-induced myométrial contractions through Ferguson’s reflex Both 
oestrogen and progesterone regulate the function o f oxytocin at the receptor level and facilitate the 
uterine response. During parturition oxytocin stimulates the production and release of arachidonic 
acid from decidual cells, potentiating its effects on the myometrium Oxytocin also stimulates
vascular smooth muscle relaxation and has an antidiuretic e ffec t'T
While it is clear that oxytocin has direct effects on the myometrium, it is recognised that oxytocin has 
no direct effect on cervical tissue composition Any changes in cervical composition associated 
with pharmacological oxytocin administration are likely to be the result of sheer stress caused by 
myométrial contractions, and the actions of other mediators of cervical ripening that are induced by 
oxytocin such as prostaglandins.
Relaxin;
Relaxin is a 6000-dalton dimeric polypeptide hormone that is structurally related to insulin and was 
first isolated in its pure form in 1926 The hormone consists of two chains, an A chain of 24 
amino acids and a B chain of 29 amino acids, that are linked by 2 disulfide bridges, with additional 
disulfide linkage in the A chain Relaxin promotes cervical connective tissue changes in both 
animals and humans.
In pregnant rats the administration of relaxin decreases cervical collagen concentration, increases 
cervical collagen solubility and increases cervical concentrations of hyaluronic acid °^®. In rats 
cervical ripening is inhibited by the administration of an antibody specific to relaxin In humans 
serum concentrations of relaxin remain constant throughout pregnancy but cervical tissue 
concentrations of relaxin rise towards the end of pregnancy ' In the human cervix relaxin increases 
gelatinase and collagenase activities, and also increases GAG synthesis
The action of relaxin during cervical ripening appears to be dependent on the presence of oestrogen. 
The administration of relaxin and oestrogen to pregnant rats at term following oophorectomy, results 
in changes similar to those of cervical ripening Oestrogen and relaxin appear to have a
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synergistic effect on increasing porcine cervical collagen synthesis and secretion, and oestrogens 
regulate the binding of relaxin to cervical cells Relaxin therefore maintains the cervical ripening 
process in the presence of oestrogen. Relaxin regulates the binding of the oestromedin, IGF-1, to 
human decidudal cells and it is possible that this is the mechanism by which relaxin regulates the 
effects of oestrogen in the cervix.
Relaxin also has effects in the myometrium and other tissues. Purified porcine relaxin inhibits 
spontaneous contractility of myometrium from pregnant rats and pigs in vitro Relaxin also
inhibits the spontaneous contractility of non-pregnant human myometrium in vitro However the
same effects could not be demonstrated on pregnant human myometrium in vitro and it appears 
that human relaxin only has a minor effect on myométrial activity in late pregnancy
Relaxin stimulates the release of prorenin from cultured human decidual cells and also regulates the 
synthesis and release of decidual prolactin. Relaxin increases insulin binding to adipocytes and may 
have a regulatory role in lipid metabolism during pregnancy. Growth hormone secretion may also be 
regulated by relaxin, and relaxin may be involved in the expansion of plasma volume that is seen in 
pregnancy, which is caused by re-setting of the plasma osmolality-arginine vasopressin system
Prostaglandins:
The administration of exogenous prostaglandins produces cervical ripening at any stage in pregnancy 
Prostaglandins are a closely related family of C20 carboxylic acids. Prostaglandins consist of a 
pentane ring that has two fetty acyl chains attached to adjacent carbons. The structure of the pentane 
ring differs between the different sub-classes of prostaglandins (A, B, C, D, E. F or J). Prostacyclin 
(PGI^) and thromboxane A  ^ have a different ring structure to the other prostaglandins. Each
prostaglandin also has a numeric designation (1, 2, 3) that indicates the number of double bonds in 
the fatty acyl backbone
The biological effects of prostaglandins are mediated via receptors that are attached to the cell 
membrane or intracellular organelles. These receptors are specific to the type of prostaglandin as
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determined by the pentane ring. However prostaglandin receptors do not distinguish between the 
molecules in the fatty acyl backbone.
The most common precursor for the synthesis of prostaglandins is arachidonic acid {all-cis-5, 8, 11, 
14 eicosatetraenoic acid). Arachidonic acid and other precursors are liberated from the cell 
membrane by phospholipases, principally phospholipase A^ (PLA^). Following their release 
arachidonic acids are metabolised to a number of biologically active compounds, which are known as 
eicosanoids. Prostaglandins are derived from these eicosanoids via the eyclo-oxygenase (COX) 
pathway. Leukotrienes and lipoxins are also derived from arachidonic acids
Cyclo-oxygenase exists in two forms. COX-1 is present in a wide variety of tissues and is known as 
non-inducible COX. COX-2 is found in only a small number of tissues and is referred to as inducible 
COX. COX-2 is expressed in very low quantities under basal conditions. However the induction of 
COX-2 is of greater significance in the regulation of COX activity. Non-steroidal anti-inflammatory 
drugs prevent cervical ripening by inhibiting prostaglandin synthesis The local administration of 
the COX-2 antagonist nimesulide, to pregnant rats also inhibits cervical ripening
Prostaglandin E^, F^  ^ and are important regulators of cervical ripening PGE^ appears to be a 
more important mediator of cervical ripening than PGF^ , while the role of PGl^ in the process of 
cervical ripening remains unclear
Prostaglandins appear to promote cervical ripening by inducing qualitative and quantitative changes 
in cervical collagen and by altering the GAG/proteoglycan composition. Animal studies have shown 
a variety of effects of prostaglandins on cervical composition. PGE^ administered to pregnant rats at 
term appears to have no significant effect on cervical hydration, total collagen content, and appears to 
decrease the quantity of soluble collagen In the same study PGF^^ decreased cervical tissue 
hydration, had no effect on total cervical collagen content or quantity of soluble collagen. The 
inhibition of cyclo-oxygenase produced no significant effects on total collagen content but did 
decrease the amount of soluble collagen. The author concluded that prostaglandins do not act alone 
in the regulation of cervical ripening
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El Maradny et al demonstrated that the administration of PGE^ to pregnant rabbits, had no effect on
total cervical water content, but an increase in cervical hydration was seen following the 
administration of repeated doses of prostaglandin In the same study the administration of PGE^
increased the number of neutrophil polymorphs, significantly decreased the total collagen 
concentration, but had no effect on MMP activity.
In humans the administration of the prostaglandin analogue gemeprost in the first trimester of 
pregnancy significantly reduces total collagen content PGE^ administration was associated with
an influx of neutrophil polymorphs. Conversely Greer et al demonstrated that the administration of 
gemeprost had no statistically significant effect on cervical GAG concentrations
Norman et al showed that cervical biopsies taken following delivery, from pregnant women who had 
received intra-cervical PGE^ at term, had reduced collagen content compared to non-pregnant
controls In women who had received PGE^ there were no differences in collagen content between
women who delivered by caesarean section and those who delivered vaginally, suggesting that 
cervical remodelling had occurred early in labour. PGE^ stimulates the synthesis of GAG in cervical
fibroblasts in vitro Norman et al demonstrated that women who had been treated with PGE^ in
vivo had significantly increased cervical proteoglycan synthesis, particularly larger proteoglycans 
such as PGL and biglycan, compared to pregnant and non-pregnant controls
The mechanisms by which prostaglandins regulate cervical ripening are not frilly understood. The 
effects of prostaglandins on the cervix may not be the result of direct activation of MMPs that degrade 
collagen fibres Prostaglandin analogues applied to the human cervix decrease collagen cross- 
linking and it has been suggested that prostaglandins activate poteases that cleave cross-links
between cervical collagen fibrils
In cervical ripening prostaglandins may also act as vasodilatory agents and increase vascular 
permeability, thereby facilitating inflammatory cell infiltration During cervical ripening
prostaglandins may also promote the adhesion of granulocytes to the vascular endothelium prior to
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chemotaxis. PGE^ increases the expression of the endothelial adhesion molecule ICAM-1 in
umbilical vein endothelial cells in vitro Denison et al demonstrated that PGE^ release from the
cervix inhibited the release of secretory leukocyte protease inhibitor (SLPI) SLPI is a strong 
inhibitor of neutrophil ftmction and elastase release. A fall in SLPI activity would result in neutrophil 
recruitment and activation, and thus facilitate the process of cervical ripening.
There is evidence to support that prostaglandins are one of the links between the endocrine changes 
that occur at the end of pregnancy and the cervical changes that are seen during parturition. 
Oestradiol stimulates prostaglandin production within the uterus The induction of cervical 
ripening in sheep using oestradiol is associated with an increased production of prostaglandins from 
the cervix It is likely that progesterone inhibits prostaglandin synthesis and enhances
prostaglandin catabolism Antiprogestins have the opposite effects However in vitro
studies have shown that progesterone and dexamethasone do not appear to effect cervical PGE^
release
Prostaglandin synthesis and bioavailability may therefore be regulated by other non-endocrine factors. 
Both PGE^ and PGF^^ are released from the fetal and maternal sides of intact fetal membranes in
response to bacterial endotoxin (lipopolysaccharide) in vitro Bacterial endotoxin is a component 
of the cell wall of gram-negative bacteria. Infection has been implicated in the pathogenesis of pre­
term labour. However bacterial endotoxin does not appear to cross the intact fetal membrane and 
this prompted Rajasingham et al to suggest that another factor, perhaps a cytokine, was important in 
stimulating prostaglandin synthesis in response to infection.
It is now apparent that prostaglandins regulate cervical ripening by altering cytokine activity 
Prostaglandins inhibit the production of IL-1 from macrophages and peripheral blood monocytes 
PGE^ stimulates the release of IL-8 from human cervical tissue in vitro In extra-uterine sites 
PGE^ acts synergistically with IL-8 to promote neutiophil chemotaxis The prostaglandin 
analogue misoprostol decreases IL-ip in the pregnant rat cervix in vitro
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During cervical ripening prostaglandin activity appears to be mediated by cytokines. However there 
is also evidence to suggest that cytokines regulate prostaglandin activity. Prostaglandin production is 
regulated by the availability of arachidonic acid, via an increase in phopsholipase (PLA^) activity,
and also cyclo-oxygenase (COX) activity. IL-1, IL-6 and TNF increase PLA^ activity in a variety of
animal and human cells in vitro In the rat glomerular mesangial cells TNF induced PLA^ release
in vitro is blocked by dexamethasone IL-1 and TNF also stimulate COX
IL-1 stimulates the production of prostaglandins by fetal membrane cells TNF-a stimulates the 
production of PGE^ from amnion cells in vitro Anti-IL-ip inhibits lipopolysaccharide induced
PGEg production from human decidual cells in vitro Klim et al also demonstrated that TGF-P2 
also inhibits lipopolysaccharide induced PGE^ production from human decidual cells in vitro. PGE^ 
release from the cervix is stimulated by nitric oxide in vitro, while conversely IL-8 has no effect on 
PGE^ release from the cervix in vitro
Therefore prostaglandin activity is essential for successfiil cervical ripening to occur. Prostaglandins 
appear to be one of the links between the endocrine changes that are seen in the later stages of human 
and animal pregnancy, and the inflammatory changes that are visualised in the cervix during 
parturition.
Nitric Oxide:
It is now clear that nitric oxide (NO) is a crucial factor in the process of cervical connective tissue 
remodelling during parturition in both animals and humans NO, previously described as 
endothelial dependent relaxing factor, is a small, uncharged gas molecule that is an important 
biological mediator in humans. It is a free radical with a half-life of a few seconds NO is 
synthesised from the amino acid 1-arginine by the enzyme nitric oxide synthase. There are three 
isoforms of the enzyme; neuronal, inducible, and endothelial nitric oxide synthase (NOS I, II and III).
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Haemodynamic Effects o f  NO:
In the vascular system NO induces vasodilatation, inhibits platelet aggregation, prevents neutrophils 
and platelet aggregation to endothelial cells, inhibits smooth muscle cell proliferation and migration, 
and maintains endothelial cell barrier ftmction In the non-pregnant state NO is thought to play 
an important role in the control of systemic blood pressure, by maintaining resistance vessels in a 
constant state of relaxation. NO relaxes smooth muscle by activating soluble guanylate cyclase 
There are several mechanisms controlling the concentration of NO at the vascular site; an increase in 
the basal release of NO will reduce resistance and increase flow; NO may be released in response to 
specific receptor activation; NO may be released via non-receptor mechanisms such as neuronal 
stimuli; NO may also be released in response to sheer stress
In normal human pregnancy there is a marked increase in intravascular volume, heart rate and 
cardiac output. Endogenous NO, in conjunction with other agents such as prostacyclin, has been 
implicated in the mechanism of pregnancy-induced vasodilatation In the rat NO is an important 
regulator of maternal blood pressure in pregnancy This appears to be oestrogen dependent
NO and the Utero-Placental Circulation:
Pregnancy is associated with an increase in flow in the utero-placental circulation along with the 
development of the feto-placental circulation There is continuous forward flow velocity in the 
umbilical artery, which suggests that there is low impedance to flow in the placental circulation. In 
the pregnant guinea pig NO is important for uterine artery relaxation The increase in NOS 
activity in pregnant guinea pigs is also oestrogen dependent Chang et al showed that the infusion 
of a NOS inhibitor to sheep increased feto-placental resistance and reduced umbilical artery flow 
In humans endogenous NO appears to contribute to the maintenance of vasodilatation in the utero­
placental circulation in order to preserve low resistance to flow In humans NO relaxes both 
placental and umbilical vessels in vitro In the human utero-placental circulation it appears
that NO is produced locally in response to shear stress caused by blood flow
30
NO and the Myometrium:
In animals both NOS II expression and NO production in the uterus are increased during pregnancy 
to maintain uterine quiescence In animals uterine NOS II expression and NO
production decrease during term and pre-term labour However these changes do not appear to
occur in humans NO donors relax the myometrium and these agents have been proposed as 
tocolytic agents in the management of pre-term labour NO donors have also successfiilly been
used to treat intrapartum fetal distress caused by uterine hypertonus
NO and Inflammation:
NO has pro-inflammatory properties and has been implicated in tissue damage and apoptosis. The 
NOS II system is important in tissue remodelling and inflammation. The induction of NOS II can 
lead to sustained high concentrations of NO, promoting inflammatory effects such as vasodilatation, 
oedema, cytotoxicity, tissue remodelling and the activation o f cytokines Therefore if  NO plays a
prominent role in the inflammatory process, it would seem likely that it plays a vital role in the 
process of cervical ripening.
NO and Cervical Ripening:
Animal models suggest that NO is another important factor in the process of cervical ripening. In the 
rat cervix there is a low production of NO during pregnancy and a high production of NO during 
term and pre-term labour Treatment o f pregnant guinea pigs with an inhibitor of NOS (L- 
NAME) induces pre-term parturition but delays cervical ripening L-NAME treatment of
pregnant rats also causes delayed cervical ripening Lipopolysaccharide (LPS), a product of 
bacterial infection, can induce cervical ripening in pregnant rats that can be inhibited by L-NAME 
This suggests that NO is important in the pathogenesis of infection-induced pre-term labour. In 
guinea pigs the direct application of an NO donor, sodium nitroprusside (SNP), to the cervix can 
induce macroscopic changes similar to cervical ripening, along with histological evidence of cervical
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connective tissue remodelling The intra-cervical application of SNP to pregnant guinea pigs 
induces cervical ripening by decreasing the amount of collagen cross-links
NO is also important factor in human cervical ripening. There is an increase in NO production in the 
human cervix during the ripening process. Human cervical biopsies obtained from women within 10 
minutes of delivery show an increase in NOS II expression compared with non-pregnant controls 
The NO donors, isosorbide mononitrate and glyceryl trinitrate are effective at reducing the force 
required to dilate the cervix prior to surgical termination, in women in the first trimester of 
pregnancy, when compared to no treatment Although these NO donors were not as effective as the 
PGE2 analogue gemeprost at inducing cervical changes, this study still demonstrates that NO is a
factor in human cervical remodelling. Pregnant women who deliver prematurely have higher 
concentrations of the metabolites of NO in their vaginal secretions between 22 and 32 weeks 
gestation, compared to those women who deliver at term This provides fiirther evidence that NO 
is another regulator of the process of parturition.
The mechanisms by which NO regulates cervical ripening are not yet fully understood, but are again 
likely to link with the endocrine and biochemical changes that are associated with parturition. There 
is evidence from animal studies to suggest that NO influences MMP production in tissues. NO 
stimulates gelatinase activity in rat mesangial cells Incubation of rabbit articular chondrocytes
with IL-1 stimulated NO release and also MMP-2 (gelatinase) and MMP-9 release In cultured 
chondrocytes NO can also influence GAG synthesis The full effect of NO on collagen and
proteoglycan metabolism in both the animal and human cervix has yet to be determined. In humans 
the in vivo and in vitro administration of NO donors to cervical tissue obtained from women in the 
first trimester of pregnancy does not have any significant effect on cervical MMP-2, MMP-9 and 
TIMP secretion
Synthesis of NO can be altered by endocrine factors and also by cytokines In rats uterine NO 
production is gestationally regulated and progesterone dependent IL-1 (3 induces iNOS expression 
in rat ovarian tissue in vitro In humans, the pro-inflammatory cytokines IL-6, IL-8 and TNF-a 
are associated with the induction of NO production during the acute phase of sepsis Inducible
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NOS is activated by the pro-inflammatory cytokines IL-1, IFN-y and TNF-a, and inhibited by the 
anti-inflammatory cytokines IL-4, IL-IO and TGF-p IL-1 appears to be the most effective
cytokine in stimulating NO release from iNOS containing cells Neutrophils and macrophages 
cells are likely to be the source of NO during cervical ripening as they contain iNOS and are capable 
of producing large quantities o f NO The placenta is another potential source of NO
NO may also influence other mediators of cervical ripening. NO is a powerful inducer of COX-2 and 
elevates local PGE^ concentrations in inflamed tissues Local application of an NO donor to the
human cervix increases PGF^^ and decreases thromboxane A2 synthesis NO also stimulates IL-8
and PGE^ release from the human cervix in vitio Further work is required to assess what effects
NO has on other cytokines involved in cervical ripening, in order to determine the exact role of NO in 
the ripening cascade.
Therefore NO represents another metabolic mediator of the cervical ripening, acting at the end of the 
process During cervical ripening it is likely that NO stimulates prostaglandin synthesis by inducing 
COX-2 and may act along with PGE2 to increasing vascular permeability, cytotoxicity and by 
promoting tissue damage. NO may activate other MMPs and alter glycosaminoglycan composition by 
mechanisms that have as yet not been determined. NO may also regulate apoptosis again by 
mechanisms that are still to be determined.
Conclusion:
To conclude this section I will attempt to summarise the sequence of events that occur in the female 
reproductive tract in the later stages of pregnancy, in order to provide an overview of the physiology 
of parturition. Some of what follows is speculative and may of course be disproved by future research.
During pregnancy there are profound changes in the composition of the cervix that facilitate the 
process of cervical ripening. There is both a reduction in total cervical collagen concentration with 
an associated increase in immature collagen content. There is a marked increase in cervical tissue 
hydration. The total cervical proteoglycan concentration is halved and there are also qualitative
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changes in the cervical GAG composition. These changes act to destabilise the cervical extra-cellular 
matrix.
The histological and biochemical changes of cervical ripening are similar to an inflammatory 
reaction. During cervical ripening there is vasodilatation and an increase in vascular permeability 
that is followed by an influx of neutrophilic polymorphonuclear leukocytes and macrophages into the 
cervical stroma. Cervical ripening is associated with apoptosis of cervical smooth muscle cells and 
fibroblasts, the significance of which is uncertain. Neutrophil polymorphs are the main source of 
matrix metalloproteinases (MMPs) during cervical ripening. MMPs are enzymes that are essential for 
collagen degradation. Leukocyte elastase is also essential for successful cervical connective tissue 
remodelling. The activation of these enzymes promotes the fiirther coimective tissue changes that are 
required for successful parturition.
Human parturition may be thought of as consisting of two phases; a preparatory phase which is 
cervical ripening, and a phase of myométrial activity that is associated with progressive cervical 
dilatation, known as active labour. Human parturition appears to be regulated by a number of factors. 
These factors, whilst independent of one another, can regulate other factors in the parturition chain. 
It appears that once the cascade of events in human parturition has been initiated, these factors 
interact with one another to ensure that successful parturition occurs.
The activation of the fetal hypothalamic-pituitary-adrenal-placental axis appears to be the trigger for 
human parturition. This axis may be triggered by maternal or fetal stress, or by a “biological clock” 
within the mother, fetus or placenta. This activation of this axis will produce a rise in fetal cortisol, 
DHEA and placental CRH. Fetal cortisol may displace progesterone fi’om glucocorticoid receptors in 
the placenta, myometrium and cervix, thereby simulating progesterone “withdrawal” . In the 
placenta the “withdrawal” of progesterone in conjunction with an increase in fetal cortisol production 
will promote placental CRH synthesis. The mediators of cervical ripening will also promote the 
synthesis of placental CRH. IL-1 and prostaglandins promote the production of placental CRH. 
Placental CRH stimulates the release of fetal ACTH fi-om the fetal pituitary gland, which in turn
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stimulates further production of fetal cortisol from the fetal adrenal cortex. A positive “feed-forward” 
loop is therefore established ensuring a rise in fetal cortisol, DHEA and placental CRH.
In the placenta DHEA is converted to oestradiol. Oestradiol increases myométrial gap junction 
formation, increases the number of myométrial oxytocin receptors, and stimulates prostaglandin 
formation. These changes are essential to promote myométrial contractions. Oxytocin release from 
the pituitary will fiii-ther promote myométrial activity. Myométrial contractions, along with pressure 
from a descending fetal presenting part, cause mechanical stress on the cervix. Mechanical stress, 
along with the hormonal changes of parturition, is important in initiating the inflammatory cascade 
of cervical ripening.
Prostaglandins, NO, relaxin and cytokines regulate the connective tissue re-modellmg that occurs in 
the cervix during cervical ripening, in response to the endocrine changes of parturition and 
mechanical stress. Stretching of the cervix may result in an increase in IL-8 and prostaglandin 
activity, most likely from cervical fibroblasts in response to IL-1. Progesterone “withdrawal” leads to 
increased expression of endothelial adhesion molecules allowing the adhesion of leukocytes to the 
vascular endothelium prior to chemotaxis. IL-8 is a power fill neutrophil chemotactic agent, and 
promotes neutrophil activation and increases vascular permeability. PGE2 stimulates the release of 
IL-8 and may act synergistically with IL-8 to promote neutrophil chemotaxis.
Prostaglandins may also act as vasodilator agents and increase vascular permeability, further 
facilitating inflammatory changes. The local endocrine changes, namely a rise in oestradiol and a 
“withdrawal” of progesterone also stimulate prostaglandin production and reduces prostaglandin 
catabolism. The “withdrawal” of progesterone will also stimulate NO production from neutrophil 
polymorphs possibly mediated by IL-6, IL-8 and TNF-a. NO may promote further PGE^ release from
the cervix via COX-2 induction and NO may act along with PGE^ in increasing vascular 
permeability, cytotoxicity and by promoting tissue damage. IL-1, IL-6 and TNF also increase the 
production of prostaglandins via increased PLA^ activity.
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In the cervix oestrogens may initiate apoptosis of cervical smooth muscle cells and fibroblasts and 
also promote cervical eosinophilic infiltration. Fetal cortisol, NO and TNF-a may also regulate 
apoptosis of cervical cells. Oestrogens also regulate the binding of relaxin to cervical cells. These 
effects of oestrogen during cervical ripening may be mediated by insulin-like growth factor.
The final stages of cervical ripening result in the activation of MMPs, and hence connective tissue 
remodelling. The “withdrawal” of progesterone allows IL-1 to induce the expression of MMP and 
down-regulate the expression of TIMP. The effects of IL-1 on MMP production are mediated by 
protein kinase C. IL-I and IL-8 stimulate MMP release from neutrophils and fibroblasts and also 
stimulate fibroblast hyaluronic acid production, altering the cervical glycosaminoglycan structure. 
DHEA appears to act synergistically with IL-8 by increasing MMP activity. Relaxin increases MMP 
activity, and also increases cervical GAG synthesis. TNF-a and TGF-p may also be involved in 
cervical MMP production. NO may also stimulate MMP activity either directly, or via other mediators 
such as IL-I. NO may also influence cervical GAG synthesis.
The overall effect of the connective tissue changes that occur in the cervix during parturition facilitate 
fiirther cervical remodelling during active labour and, along with myométrial contractions, should 
lead to successfiil delivery of the infant.
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II. The Induction of Cervical Ripening:
Introduction:
The decision to attempt to artificially induce labour is one that the obstetrician does not take lightly. 
The objective of artificially inducing cervical ripening and uterine contractions is to provide greater 
benefit to the health of the mother and/or the fetus than if  the pregnancy continued. The risks of the 
induction of labour are dependent upon parity, the individual’s past obstetric history and the ripeness 
of the cervix The risks of induction of labour include increased rates of caesarean section and 
operative vaginal delivery compared to women who labour spontaneously, increased rates of fetal 
distress requiring medical intervention, wound dehiscence, epidural anaesthesia, intra-partum 
pyrexia, chorioamnionitis and post-partum haemorrhage The induction of labour is associated 
with a caesarean section rate of 25 - 40%, with some series reporting a caesarean rate as high as 47%
There are many reasons as to why one would wish to initiate the potentially hazardous process of the 
induction of labour. There may be concerns regarding the well-being of the fetus; for example a 
pregnancy compromised by intra-uterine growth restriction or severe rhesus disease. Labour may be 
induced because of concerns regarding the health of the mother, for example worsening preeclampsia. 
Labour induction is occasionally performed for the convenience of the mother in the absence of any 
clear medical indication or health benefit. The risks of “social induction” must be clearly explained 
to women before the decision to induce labom* is made.
In the United Kingdom the most common indication for the induction of labour is prolonged 
pregnancy. Pregnancies that continue beyond 42 weeks gestation are associated v^ith an increased 
risk of stillbirth, neonatal and infimt mortality Induction of labour should be offered routinely to 
all women whose pregnancies continue beyond 41 weeks gestation Induction of labour during 
this time is associated with reduced caesarean section rate, reduced rate of operative vaginal delivery, 
reduced frequency of fetal distress, meconium staining, macrosomia, and decreased risk of fetal and 
neonatal death
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The aim of the induction of labour is to successfully mimic the physiological process of parturition 
leading to a vaginal delivery, whilst creating minimal discomfort and risk to the mother and fetus. 
The ideal agent used for the induction of cervical ripening and the induction of labour should be 
effective, easy to administer, acceptable to the patient, safe for both mother and fetus and cost- 
effective.
Before the induction of labour begins, the cervix should be examined to determine its “ripeness” . The 
ripeness of the cervix can be determined using the modified Bishop Score The cervical length, 
consistency, position and dilatation should be determined, along with the station of the fetal 
presenting part in relation to the ischial spines. Cervical dilatation appears to be the most important 
factor in predicting the length of the latent phase of labour and the likelihood of success of induction 
of labour
If the cervix is unfavourable (Bishop Score <7), then cervical ripening is required. When the cervix 
is favourable (Bishop Score > 7), amniotomy should be performed. In some patients, most commonly 
multiparous women, amniotomy is often enough to provoke regular myométrial activity. 88% of 
women with a fevourable cervix will labour within 24 hours by amniotomy alone Nevertheless 
following amniotomy synthetic oxytocin is usually used to stimulate active labour. If  oxytocin is 
commenced at the time of amniotomy rather than delayed, there are reduced rates of operative 
delivery, post-partum haemorrhage and a shorter time interval from induction to delivery
The first chapter of this thesis described the physiology of cervical ripening and the factors that 
initiate and regulate this process. A number of strategies have developed in an attempt to artificially 
induce cervical ripening, based on our understanding of the physiology of parturition. Once sufficient 
cervical ripening has occurred the second phase of parturition, known as active labour, may be 
induced with amniotomy and intravenous oxytocin infiision.
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Membrane Sweeping:
Membrane sweeping has been used since 1810 to promote cervical ripening prior to the induction of 
labour. During routine cervical examination, the inferior pole of chorioamniotic membranes is 
separated from the lower uterine segment using a circular “sweeping” motion of the examining finger 
that has been inserted through the cervix. This procedure is relatively non-invasive, safe, easy to 
perform and inexpensive
It is believed that membrane sweeping stimulates cervical ripening by promoting endogenous 
prostaglandin release Membrane sweeping is associated with increased phospholipase activity 
and increased serum PGF^^ metabolites
There are a number of studies that have demonstrated that membrane sweeping is effective at 
inducing parturition. Sweeping of the membranes once at term reduces the need for induction of 
labour in multiparous women with a favourable Bishop Score In women with an unfavourable 
cervix and a negative fetal fibronectin test at 39 weeks gestation, membrane sweeping every 3 days 
from 39 weeks gestation is associated with a lower gestational age at the time of delivery, a higher 
Bishop score on admission for delivery, a higher rate of spontaneous labour, a lower number of 
women requiring induction of labour, and a lower number of women who are undelivered at 42 weeks 
gestation Cammu and Haitsma demonstrated that weekly membrane sweeping is associated with 
a reduced number of primigravid women whose pregnancies progress beyond 287 days and hence a 
decreased rate of induetion of labour in these women In women with unfavourable cervices at 41 
weeks gestation daily membrane sweeping is associated with increased cervical ripening, shorter 
intervals to delivery, higher rates of spontaneous labour and reduced numbers of women requiring 
induction of labour at 42 weeks gestation compared to daily administration of prostaglandin
However, membrane sweeping once in primigravid and multigravid women at term with 
unfavourable cervices (Bishop Score <6) has little effect on the rates of induction of labour 
Sweeping the membranes once between 38 and 40 weeks gestation is not associated with an increase 
in women who progress into spontaneous labour within seven days of the procedure Multiple
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sweeping therefore appears to be more effective than single membrane sweeping, especially in 
primigravid women.
Membrane sweeping is not entirely free of risk. The potential risks of membrane sweeping are 
infection, membrane rupture and ante-partum haemorrhage from an undiagnosed placenta praevia 
Boulvain reported that membrane sweeping was not associated with any significant adverse maternal 
or fetal outcome. However membrane sweeping appears to be associated with significant maternal 
discomfort during the procedure, and the vaginal examinations are perceived to take longer 
Membrane sweeping is also associated with an increase in vaginal bleeding and uterine contractions 
prior to the onset of labour that can cause considerable maternal anxiety
Balloon Catheter Devices, and Mechanical Dilators:
Mechanical devices can be used to ripen the cervix prior to the induction of labour and are designed 
to ripen the cervix without causing uterine contractions. These techniques are useful in situations 
where induction of labour is necessary and uterine hyperstimulation is particularly undesirable, such 
as in multiparous women who have previously delivered by caesarean section, where there is a risk of 
uterine scar dehiscence, and also in pregnancies complicated by infra uterine growth restriction.
Like membrane sweeping, mechanical devices also appear to stimulate the release of endogenous 
prostaglandins from the decidua Histological examination of the cervix after such treatments 
shows an inflammatory response, with increased tissue hydration and a reduction in tissue collagen 
concentration 198
Although the aim of mechanical techniques used to stimulate cervical ripening is to avoid uterine 
hyperstimulation, these methods are not entirely free of risk. Fetal distress can occur and there are 
risks of chorioamnionitis, membrane rupture and ante-partum haemorrhage. Mechanical procedures 
used to induce cervical ripening can also cause unwanted maternal discomfort.
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The Foley single balloon catheter can induce cervical ripening, shorten the length of time between 
induction and delivery, reduce the rate of caesarean section and increase the rate of spontaneous 
vaginal delivery The use of an extra-amniotic balloon catheter device is inexpensive, safe, easy to
use and reversible It appears to be well tolerated when administered to outpatients
The Foley catheter is inserted into the cervical canal under aseptic conditions in the lithotomy 
position, the catheter balloon is filled with saline. In addition, traction may be applied to further 
encourage cervical ripening. The balloon either falls out spontaneously when cervical ripening has 
occurred, or is gently extracted at 12 hours.
The Foley catheter is as least as effective as PGE^ when used for the induction of cervical ripening, is
less expensive, and has a similar rate of intra-partum complications and delivery outcomes as PGE^
gel The Foley catheter also appears to have a shorter time interval between induction and
delivery when compared to PGE^, but in one study in which this was demonstrated, different methods
of inducing uterine activity were used once cervical ripening had been achieved, making the 
interpretation of this finding difficult Adverse effects that may result fi"om the use of the Foley 
catheter for the induction of cervical ripening include rupture of membranes, displacement of the fetal 
presenting part, vaginal bleeding, and infection However these adverse outcomes are rarely seen.
The instillation of normal saline into the extra-amniotic space via the Foley catheter fiirther promotes 
cervical ripening and is more effective than intra-vaginal and intra-cervical PGE^ in ripening the
unfavourable cervix However the installation of fluid through the Foley catheter has never
been shown to be more effective than insertion o f the Foley catheter alone.
The Atad Ripener Device is a recently developed double balloon device that operates using the same 
principle as the Foley balloon catheter, and is effective at inducing cervical ripening in 92% of 
primigravid and multigravid women The Atad double balloon device appears to cause less 
maternal discomfort than the single balloon Foley catheter, and appears to be more efficacious than 
the single balloon device and have a lower failure rate (8% vs. 16%) Further randomised-
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controlled trials are required in order to determine whether or not this device is a more acceptable 
agent than other methods of inducing cervical ripening.
Dilapan is a synthetic polyacryhiitrile hygroscopic cervical dilator that is safe and effective at 
inducing cervical ripening prior to the induction of labour Dilapan dilators are inserted into the 
cervical canal and removed 12 hours after insertion. However the use of Dilapan as a cervical 
ripening agent is not associated with any reduction in the total length of labour, nor does it reduce the 
rate of caesarean section in those women who are attending for the induction of labour who have 
received oxytocin without any ripening agent
Dihydroepiandrosterope (DHEA) and Oestrogen:
During human parturition increases in plasma dihydroepiandrosterone (DHEA) concentrations are 
associated with cervical ripening DHEA is synthesised in the fetal adrenal gland in response to fetal 
ACTH. In the placenta DHEA is converted to oestradiol. The alteration of the ratio of oestrogen to 
progesterone prior to the onset of parturition is believed to stimulate prostaglandin production that 
will in turn promote cervical ripening.
The twice-weekly intra-venous administration of 100 milligrams DHEA from 37 weeks gestation is 
associated with significant increases in Bishop Score until 14 days after first injection, compared to 
controls There was also a significantly shorter induction to delivery interval associated with 
DHEA administration. However this study does not include information regarding maternal and 
neonatal outcomes, and it is therefore difficult to comment on the safety of DHEA when used for the 
induction of cervical ripening. The use of an agent for the induction of cervical ripening that must be 
injected repeatedly is also questionable.
The local application of oestradiol cream is effective at inducing cervical ripening and is associated 
with a reduction in the caesarean section rate Oestradiol is as effective as intra-vaginal PGE2 gel 
at inducing labour with less uterine activity The administration of 4 milligrams of oestradiol 
cream into the anterior fornix at 6 hourly intervals is as effective at inducing cervical ripening as the
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intra-cervical administration of 0.5 milligrams of PGE2 gel at 6 hourly intervals, and also 
intravenous infusion of low dose oxytocin Magann et al noted that although the overall rate of 
caesarean section was high (59%), there were no differences in delivery outcomes between the three 
agents.
Despite there being some evidence to suggest that the local application of oestradiol cream is effective 
at inducing cervical ripening, the use of oestrogens to induce cervical ripening appears to have gone 
out of vogue. The studies that have investigated the effectiveness of oestrogens at inducing cervical 
ripening are small, and it seems that fiirther work is required before oestrogens can be considered as 
alternatives to those agents currently used to induce cervical ripening.
Mifepristone:
Progesterone inhibits cervical ripening Mifepristone (RU 486) is a steroid compound that 
antagonises progesterone at the receptor level Mifepristone is effective at terminating pregnancy 
in early pregnancy and at term Mifepristone increases myométrial contractility and
responsiveness to endogenous and exogenous prostaglandins and also promotes cervical ripening 
It is likely that mifepristone promotes cervical ripening by inducing collagen fragmentation and 
breakdown
The oral administration of 200 milligrams of mifepristone on 2 consecutive days is effective at 
inducing cervical ripening in pregnant women at term This regime appears to be safe, even for 
those women with a history of previous caesarean section However the oral administration of a 
single dose of 200 milligrams of mifepristone to pregnant women beyond 41 weeks gestation appears 
to have only modest effects on cervical ripening The oral administration of a single dose of 400 
milligrams of mifepristone is also effective at inducing cervical ripening A  dose of 400 
milligrams of mifepristone appears to increase the number of women who progress into spontaneous 
labour and also shortens the induction to delivery interval when compared to the oral administration 
of 2 doses o f200 milligrams of mifepristone
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The use of mifepristone for the induction of cervical ripening may not be without adverse maternal, 
fetal and neonatal adverse effects. Mifepristone may increase the incidence of uterine hypertonus 
when oxytocin is used for augmentation of labour Mifepristone has anti-glucocorticoid properties 
that do not appear to be of any clinical significance in adults, even following the administration of a 
single high dose (2 grams), or following prolonged administration (200 milligrams daily for 3 
months) Mifepristone crosses the placenta and could therefore adversely affect the fetus, in 
particular by causing neonatal hypoglycaemia
The numbers involved in studies in which mifepristone has been used to induce cervical ripening in 
pregnant women at term are too small to draw conclusions about the fetal and neonatal safety of 
mifepristone when used as a cervical ripening agent, although no significantly increased adverse 
outcomes have been seen. Therefore mifepristone might be a suitable alternative to those agents 
currently in use for the induction of cervical ripening, although further studies are required to fully 
evaluate the risks and benefits of this agent.
Oxytocin:
It is recognised that oxytocin has no direct effect on cervical tissue composition Any changes in 
cervical composition associated with pharmacological oxytocin administration are likely to be the 
result of the indirect action of sheer stress caused by myométrial contractility. However, continuous 
low dose oxytocin has been used as an effective cervical ripening agent in doses of 1 -  4 milliUnits / 
minute 2"'.
The use of intra-venous oxytocin does not appear to be more effective at inducing cervical ripening as 
locally administered PGE^ Jackson demonstrated no difference in the degree of cervical
ripening, vaginal delivery rates and successful induction rates, when low dose oxytocin infiision was 
compared with repeated intra-cervical doses of 0.5 milligrams of PGE2 gel administered at 6 hourly 
intervals In the induction of cervical ripening there appears to be a greater likelihood of vaginal
delivery within 24 hours in those women that receive PGE^ gel as opposed to oxytocin
44
Pollnow et al also demonstrated that intravenous oxytocin administration for the induction of cervical 
ripening is not as effective as locally administered PGE^ The administi ation of intra-venous
oxytocin at 2 milliUnits /  minute over 10 hours is not as effective at inducing cervical ripening as 2 
intra-vaginal doses of 4 milligrams of PGE2 gel In addition there were less successfiil inductions
and the induction to delivery interval was greater in the group that received oxytocin. There were no 
differences between the two groups for caesarean section rates, meconium stained amniotic fluid, 
Apgar Scores and umbilical cord pH.
The use of intra-venous oxytocin may also have adverse effects on both mother and fetus. Prolonged 
oxytocin use is associated with water intoxication, and may cause fetal distress due to uterine 
contractions on an unripe cervix Because of the potential to cause hyper-stimulation there are 
situations in which one would wish to avoid the use of oxytocin for the induction of cervical ripening, 
for example in patients with a history of caesarean section and or pregnancies complicated by intra­
uterine growth restriction. Oxytocin is administered as a continuous intra-venous infusion and will 
restrict patient mobility resulting in decreased patient satisfaction.
It appears that oxytocin should not be used for the induction of cervical ripening. Intravenous 
oxytocin should be reserved for the induction of myométrial contractions following amniotomy, after 
successfiil cervical ripening has been achieved by other methods.
Relaxin:
Relaxin, a large polypeptide hormone, appears to be an integral component of human cervical 
connective tissue remodelling. Relaxin has an inhibitory effect on myométrial activity in many 
species, but human relaxin appears to have only a minor effect on myométrial activity in late 
pregnancy The idea of inducing cervical ripening without stimulating myométrial activity is 
appealing.
Early studies using purified porcine relaxin demonstrated that the intra-vaginal administration of 2 
and 4 milligrams of purified porcine relaxin resulted in an increase in cervical score and a shorter
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duration of labour, when compared to placebo There was not a statistically significant
difference in cervical ripening effect between 2 and 4 milligrams of purified porcine relaxin The 
intra-vaginal administration of 2 milligrams of purified porcine relaxin to outpatients also stimulated 
cervical ripening and appeared safe No significant cervical ripening effect was demonstrated 
following the intra-vaginal administration of 4 milligrams of purified porcine relaxin to outpatients, 
suggesting that using a higher dose might promote down-regulation of cervical relaxin receptors
More recently however, the intra-vaginal administration of 1, 1.5, 2, and 4 milligrams of recombinant 
human relaxin gel produced no significant increase in cervical score when compared to placebo at 15 
hours following administration There were also no statistically significant differences in
lengths of labour, modes of delivery, and serum relaxin concentrations when comparing these doses 
of relaxin to placebo
Although intra-vaginal recombinant human relaxin, gel is not associated with adverse maternal or 
fetal outcomes, is does not appear suitable for use as a cervical ripening agent. Intra-venous relaxin 
might improve tissue availability and hence increase the likelihood of achieving cervical ripening 
Nevertheless it must be asked whether or not women attending for the induction of labour would find 
such a regime more acceptable than those agents currently used to induce cervical ripening?
Prostaglandins:
Prostaglandins are currently the most commonly used agents used to artificially induce cervical 
ripening. In the induction of cervical ripening prostaglandins increase the likelihood of vaginal 
delivery by 33% Prostaglandins used for the induction of cervical ripening are more likely than 
placebo to increase cervical score, shorten the average length of labour, promote myométrial 
contractility, and to decrease the rate of operative delivery Prostaglandins of the E series are
superior to those of the F series when used to induce cervical ripening, as the ripening effects are 
greater and the systemic adverse effects are less
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Oral, intra-cervical, intra-vaginal and intra-venous prostaglandins have all been used to induce 
cervical ripening. The local administration of prostaglandins is more effective and is associated with 
fewer systemic adverse effects than oral or intra-venous administration. A single dose of 0.5 
milligrams intra-cervical PGE^ gel is associated with a greater increase in Bishop Score compared to
a single dose of 1 milligram intra-vaginal PGE^ gel Nevertheless when comparing intra-cervical
and intra-vaginal administration of PGE^ gel at these doses, there is no difference in total duration of
labour, mode of delivery, and maternal and fetal adverse outcomes
Stempel et al showed that there was no difference in Bishop Score when comparing the 
administration of 0.5 milligrams of intra-cervical PGE^ and 5 milligrams of intra-vaginal PGE^ for
the induction of pre-labour cervical ripening Again there was no difference in total duration of 
labour, mode of delivery, and maternal and fetal adverse outcomes between the groups that received 
intra-cervical and intra-vaginal PGE^. Because the intra-vaginal method of PGE^ administration is
easier and the preparation is cheaper, it is more widely practised,
PGE^ gel may be administered on an outpatient basis and this method of inducing cervical ripening 
appears safe and cost effective The daily administration of 2 milligrams of intra-vaginal PGE^
gel between 38 and 40 weeks gestation is safe for both mother and fetus and is effective in initiating 
labour However the out-patient administration of intra-vaginal PGE^ gel does not appear to 
reduce the overall frequency of pregnancies that have exceeded their estimated date of delivery, nor 
significantly reduce the number of inductions of labour and the rates of caesarean section for these 
women There does not appear to be any increase in cervical ripening associated with repeated 
intra-cervical doses of 0.5 milligrams ofPGE^ gel when compared to placebo, in women attending for
routine out-patient antenatal surveillance beyond their estimated date of delivery Furthermore in 
this study there was no difference in the numbers of women who required induction of labour, in the 
numbers who required additional prostaglandin gel when admitted for induction of labour, and in the 
total length of labour.
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PGE^ is usually administered as a gel but is also effective at inducing cervical ripening when
administered intra-vaginally as a sustained release preparation It has been shown that 10
milligrams of PGE^, administered intra-vaginally as a continuous release preparation over 12 hours,
is at least as effective as intra-cervical doses of O.Smilligrams of PGE^ administered 6 hourly
The continuous release preparation is associated with a shorter ripening period and also a decreased 
induction to delivery interval when compared to repeated doses of intra-cervical PGE^ gel
There is no difference in the lengths of latent and active labour associated with continuous release 
PGE^ when compared to intra-cervical PGE^ and there were no significant differences in modes of
delivery and side effeet profile Nonetheless sustained release PGE^ preparations are more
likely to be associated with uterine hyper-stimulation than PGE^ gel, although the sustained release 
preparation is easily removed and the uterine effects usually disappear within 15 minutes of 
withdrawal
In the United Kingdom primigravid women with an unfevourable cervix usually receive an initial 
dose of 2 milligrams of PGE^ gel intra-vaginally. Further doses of 1 milligram may then be 
administered at 6 hourly intervals to a maximum of 4 milligrams. In multigravid women or 
primigravid women with a favourable cervix an initial dose of 1 milligram is used, followed by doses 
of 1 milligram at 6 hourly intervals to a maximum of 3 milligrams
Mackenzie and Burns showed that a single dose of 2 milligrams of PGE^ gel is as effective at 
inducing cervical ripening as 2 doses of 2 milligrams for both primigravid and multigravid women 
A single administration of 2 milligrams of PGE^ gel is also more cost effective than repeated
administration The use of prostaglandins administered in doses of 3 milligrams at 6 hourly 
intervals, followed by amniotomy and oxytocin infusion when cervical ripeness has been achieved, is 
associated with an 80% vaginal delivery rate
The use of repeated intra-vaginal doses of PGE^ gel in conjunction with the use of an intra-cervical 
single balloon Foley catheter appears to provide additional ripening effects compared to the use of 
PGE^ alone The use of a single balloon Foley catheter in combination with 4 hourly intra-vaginal
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administration of 4 milligrams of PGE^ gel is associated with more effective cervical ripening, shorter
induction to delivery interval and a higher rate of vaginal deliveries within 24 hours when compared 
to the intra-vaginal administration o f 25 micrograms of misoprostol at 4 hourly intervals 
However the use of a Foley balloon catheter in combination with the intra-vaginal administration of 
25 micrograms of misoprostol does not appear to have any significant ripening advantages when 
compared to misoprostol alone
Prostaglandin receptors are widely distributed and therefore prostaglandins administered to induce 
cervical ripening will not only have effects on the cervix, but also on other tissues. Prostaglandins 
that are administered in order to induce cervical ripening will also provoke myométrial contractions. 
Uterine hyperstimulation occurs in 7% of cases The hyper-stimulation of uterine activity with an 
unripe cervix can provoke fetal distress and also placental abruption, requiring emergency delivery by 
caesarean section. There are also prostaglandin receptors within the gastro-intestinal tract and lungs 
and prostaglandins may induce nausea, vomiting, diarrhoea and asthmatic episodes.
The prostaglandin Ei analogue misoprostol is also more effective than placebo at stimulating cervical 
ripening Misoprostol has advantages over PGE^ gel as it is far less expensive, and is easier to
administer Initial studies comparing the intra-vaginal administration of misoprostol with intra- 
cervical PGE^ suggested that misoprostol was more effective than PGE^ at inducing cervical ripening
and associated with a shorter induction to delivery time interval
However in these studies there were some concerns about potential harmful effects of misoprostol. 
Wing et al reported that whilst there were no differences in the frequency of abnormal fetal heart rate 
patterns, the administration of 50 micrograms of misoprostol at 3 hourly intervals was associated with 
an increase in myométrial activity and with the passage of thick meconium, when compared to the 
intra-cervical administration of 0.5 milligrams of PGE^ gel at 6 hourly intervals Buser et al also
reported an increase in non-reassuring fetal heart rate patterns in conjunction with uterine hyper­
stimulation, and an increase in the frequency of caesarean section associated with the administration 
of 50 micrograms of misoprostol at 4 hourly intervals
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Conversely Chuck and Huffaker concluded that the intra-vaginal administration of 50 micrograms of 
misoprostol for the induction of cervical ripening was more effective and as safe as the intra-cervical 
administi-ation of PGE^ at 4 hourly intervals The intra-vaginal administration of 50 micrograms
of misoprostol at 4 hourly intervals is as safe and effective at inducing cervical ripening as extra- 
amniotic saline infusion via a Foley single balloon catheter Indeed in this study the rate of 
caesarean section was low (23%), demonstrating the effectiveness of both agents at inducing cervical 
ripening.
Gottschall et al demonstrated that the administration of a single dose of 100 micrograms of 
misoprostol intra-vaginally is effective at inducing cervical ripening and did not appear to be 
associated with greater rates of uterine hyper-stimulation, or abnormal fetal heart rate patterns when 
compared to the administration of a single dose of 5 milligrams of intra-vaginal PGE^ The
administration of 25 micrograms of misoprostol at 3 hourly intervals does not appear to be associated 
with an increase in myométrial activity or the occurrence of thick meconium, and is effective at 
inducing cervical ripening when compared to intra-cervical PGE^
Misoprostol is also effective at inducing cervical ripening in pregnant women at term following oral 
administration Although not as effective as vaginal administration of misoprostol at inducing 
cervical ripening, there is a lower rate of caesarean section for non-reassuring fetal heart rate pattern 
associated with the oral administration of misoprostol The oral administration of 50 micrograms 
of misoprostol at 4 hourly intervals is as effective at inducing labour as the Foley balloon catheter 
used in combination with oxytocin infusion in multiparous women The rates of uterine 
hyperstimulation in this study were significantly lower in the group of women that received repeated 
doses of misoprostol compared to the Foley catheter-oxytocin group. There were no significant 
differences between the modes of delivery or adverse outcomes. The oral administration of 
misoprostol for the induction of labour appears to be less efficacious in nulliparous women The 
oral administration of 25 micrograms of misoprostol appears to be safe and effective at inducing 
labour
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A meta-analysis comparing PGE^ and misoprostol used for the induction of cervical ripening, showed 
that overall there was a shorter induction to delivery interval associated with misoprostol. However, 
misoprostol administration was associated with a higher incidence of uterine hyper-stimulation, and 
higher rates of abnormal fetal heart rate patterns and higher frequency of the presence of meconium 
stained liquor There was insufficient power in the meta-analysis to comment on the safety of 
misoprostol with regard to perinatal outcomes. This suggests that for the moment PGE^ should
remain the prostaglandin of choice for the induction of cervical ripening.
The Future - Cytokines and Nitric Oxide Donors:
There are many factors that regulate the inflammatory-like process of cervical ripening. In recent 
years it has been recognised that cytokines and nitric oxide (NO) are important regulators of 
physiological cervical ripening in both animals and humans.
IL-1, IL-8 and TNF-a have been suggested as potential cervical ripening agents The
maternal, fetal and neonatal effects of these cytokines following administration to pregnant women at 
term are unknown. Preliminary studies should involve in vitro analysis of the effects of these 
cytokines on human cervical tissue, followed by their administration to pregnant women in the first 
trimester prior to surgical termination of pregnancy, in order to gain some evidence of effectiveness at 
inducing cervical ripening and safety in humans. Subsequent studies should then focus on using 
these cytokines to induce cervical ripening at term, with particular attention on maternal, fetal and 
neonatal adverse outcomes.
NO donors have also been proposed as alternatives to other agents that are currently used to induce 
cervical ripening ®. In animals NO production in the uterus is increased during pregnancy to
maintain uterine quiescence In animals uterine iNOS expression and NO production
decrease during term and pre-term labour However these changes do not appear to occur in 
humans However, in humans NO donors relax the myometrium and these agents have been 
proposed as tocolytic agents in the management of pre-term labour NO donors have also
successfully been used to treat intrapartum fetal distress caused by uterine hypertonus The idea of
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stimulating cervical ripening without myométrial activity is appealing and this is one reason why NO 
donors could be more acceptable than those agents that are currently used for the induction of cervical 
ripening.
In the pregnant guinea pig NO is important for uterine artery relaxation Endogenous NO appears 
to contribute to the maintenance of vasodilatation and hence flow, in the utero-placental circulation 
The use of a cervical ripening agent that promotes utero-placental vasodilatation could be useful 
in situations where there is evidence of fetal compromise, for example in pregnancies complicated by 
intra-uterine growth restriction. This is another reason why NO donors could be more advantageous 
than agents that are currently used for the induction of cervical ripening.
The NO donor, sodium nitroprusside (SNP) is effective at inducing cervical ripening in guinea pigs 
In humans the NO donors, isosorbide mononitrate and glyceryl trinitrate (GTN), are effective at 
inducing cervical changes in the first trimester of pregnancy Although these NO donors were not 
as effective as the PGE^ analogue gemeprost at inducing cervical ripening a subsequent study showed
that NO donors induced cervical changes with less adverse effects than gemeprost
However NO is an important regulator of the maternal vasculatm e and the administration of NO 
donors to pregnant women at term could have profound cardiovascular effects. It is likely that NO is 
also an important regulator of the fetal vascular system, and NO donors may also induce adverse fetal 
cardiovascular events.
There are currently no published studies examining the maternal and fetal haemodynamic effects of 
NO donors that are administered intra-vaginally to pregnant women at term for the induction of 
cervical ripening. NO donors would appear to be effective at inducing cervical ripening at term in 
animals and during the first trimester of pregnancy in humans. Whether or not NO donors are 
effective at inducing cervical ripening in pregnant women at term remains to be seen. Before this 
question is answered the effects of NO donors on maternal and fetal haemodynamics needs to be 
assessed. This will pave the way for further studies examining the effects of NO donors on cervical 
ripening in pregnant women at term.
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III. The Vaginal Application of the Nitric Oxide Donor Isosorbide Mononitrate for the 
Induction of Cervical Ripening: A Randomised Controlled Trial to Determine Effects on 
Maternal and Fetal Haemodynamics:
Introduction:
The ideal agent for the pharmacological induction of cervical ripening should be easy to administer, 
cost effective, acceptable to both patient and clinician and produce adequate cervical change with 
minimal maternal and fetal adverse effects. In the United Kingdom the agent most widely used for the 
induction of cervical ripening is intra-vaginal prostaglandin Eg gel. However prostaglandins are not 
without adverse effects. These include uterine hyper stimulation, and subsequent fetal compromise, 
as well as gastro-intestinal upset (see chapter II for review).
Nitric oxide (NO) is responsible for the activity of endothelial dependent relaxing factor and is an 
important biological mediator in humans NO exerts its effects in part via the stimulation of
guanylate cyclase, and acts as a generalised smooth muscle relaxant. NO mediated smooth muscle 
relaxation is seen not only in vascular smooth muscle, but also in gastric smooth muscle, and the 
myometrium. It is now apparent that NO is another crucial factor in the regulation of cervical 
ripening (see chapter 1 for review).
NO donors are a class of drugs that liberate NO in vivo. These drugs have been used for over one 
hundred years in the treatment of ischaemic heart disease and cardiac failure. Within obstetrics NO 
donors have been used to induce myométrial relaxation in the treatment of pre-term labour 
254,255^  uterine hyperstimulation to facilitate fetal extraction during caesarean section and to 
assist with the manual removal of a retained placenta NO donors have also been used to improve 
fetal blood flow
Several authors have suggested that NO donors could be considered as alternatives to prostaglandins 
for the induction of cervical ripening The idea of stimulating cervical ripening without
stimulating myométrial activity is appealing. The use of a cervical ripening agent that also would not
53
adversely affect the utero-placental circulation is also beneficial to the fetus, especially in 
circumstances in which there is evidence of utero-placental insufficiency. However one area of 
concern regarding the use of NO donors to induce cervical ripening is the potential risk of maternal 
hypotension as a consequence of the systemic vasodilatory effects of NO. Any fall in maternal blood 
pressure could reduce utero-placental blood flow, and cause fetal compromise.
In humans the intra-vaginal administration of 40 milligrams of the NO donor isosorbide mononitrate 
(IMN) is effective at inducing cervical ripening in the first trimester of pregnancy^. Furthermore in 
the first trimester of pregnancy intra-vaginal IMN has fewer adverse effects than the prostaglandin 
analogue gemeprost when used to induce cervical ripening Before studies are performed to 
determine the efficacy of intra-vaginal IMN as a cervical ripening agent in pregnant women at term, 
it is important to determine the effects of this agent on maternal and fetal haemodynamics. The third 
chapter of this thesis will therefore present the results of a study that principally aims to determine the 
maternal and fetal haemodynamic effects following the intra-vaginal administration of IMN to 
pregnant women at term during the induction of labour.
Methods:
The study was performed at the Glasgow Royal Maternity Hospital between August 1998 and July 
1999. Prhnigravid women who were attending for the induction of labour were asked to participate 
in the study. The local ethics committee granted approval. Written informed consent was obtained 
from each participant prior to recruitment (Appendix I).
Women who wished to participate in the study were assessed by vaginal examination. Assessment of 
the cervix included an assessment of consistency, length, dilation, position and station of the fetal 
presenting part as described by Bishop in 1964 and modified by Calder in 1977 A
cardiotocograph was performed to ensure that there was no acute fetal compromise. An ultrasound 
scan was performed to measure fetal abdominal circumference and the amniotic fluid index (the sum 
of the maximum vertical cord-free pockets obtained from each of the four quadrants of the uterus). 
Women with the following characteristics were excluded: cervix with a bishop score >7, multiparity.
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multiple pregnancy, history of unexplained antepartum haemorrhage, pregnancy induced 
hypertension/preeclampsia, breech presentation, fetal abdominal circumference <5‘‘‘ centile for 
gestational age, amniotic fluid index <5**' centile for gestational age, history of cardio-respiratory 
illness, headache, or a non-reassuring fetal cardiotocograph.
Participating women were randomised to receive one of three treatments. The first group received 20 
milligrams IMN (one tablet) administered into the posterior fornix of the vagina. The second group 
received 40 milligrams IMN (two tablets) administered into the posterior fomix of the vagina. The 
third group was the control group and received a vaginal examination only. The treatment options 
were randomised using random number tables in groups of twelve (block randomisation) by the 
academic supervisor. Dr Jane Norman.
Treatment allocations were placed into opaque envelopes numbered sequentially with a unique study 
number and sealed. Following recruitment of each patient to the study, the envelopes were opened in 
order by an independent observer (one of the medical staff of the Glasgow Royal Maternity Hospital), 
who then administered the treatment. The independent observer then discarded information on the 
treatment allocation, and the unique study number was used to code the patients’ measurements. AE 
Nicoll subsequently performed all the measurements on both mother and fetus whilst blind to the 
treatment allocation. Participating women also remained blind to the treatment received. At the end 
of the study period, the treatment allocation used for each unique study number was revealed, and the 
results analysed.
Maternal pulse, maternal blood pressure and fetal heart rate were recorded, immediately prior to 
treatment and subsequently every 30 minutes using an electronic machine. The fetal
heart rate was recorded continuously using a cardiotocograph monitor from 30 minutes before 
treatment to the end of the study period. The umbilical artery resistance index and pulsatility index 
were determined at baseline, at 180 minutes and 330 minutes using continuous wave Doppler 
ultrasound. The umbilical artery Doppler studies were performed with the patient in a 15°left lateral 
tilted position. A freely floating loop o f cord was identified using real time imaging (Ultramark 4 
Plus, 3.5 MHz curvilinear probe). In the absence of fetal body or breathing movements, signals were
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then collected from the umbilical artery using a hand-held 4 MHz continuous was probe {Sonicaid 
vasoflo S). Resistance index (Rl) and pulsatility index (PI) were measured from three consecutive 
uniform waveforms. These Doppler recordings were made by the same observer (AE Nicoll), who 
was blinded to the allocated treatment.
Participating women were asked to complete a symptom questionnaire immediately before the 
administration of the treatment and again at 360 minutes (Appendix 11). This questionnaire asked 
whether or not the following symptoms were present; headache, drowsiness, nausea, indigestion, 
abdominal pain, pelvic pain, bloating, loss of appetite, diarrhoea, constipation, breast pain, faintness, 
tiredness, hot flushes, vomiting and dysuria.
Cervical score was assessed immediately prior to recruitment and again at 360 minutes in order to 
assess for change in cervical score. Both examinations were performed by the same observer (AE 
Nicoll), who remained blind to the treatment allocation. I f  the cervical score remained less than 7 at 
360 minutes after treatment allocation, participating women received cervical "priming" with intra- 
vaginal PGE2 gel in accordance with the local induction of labour protocol. Women with a cervical 
score greater than 7 underwent forewater amniotomy the following morning, again in accordance 
with the local induction of labour protocol.
The following parameters of the subsequent labour and delivery were recorded: prostaglandin and 
oxytocin requirements, mode of delivery, length o f labour for women who had a vaginal delivery, 
analgesia used during labour, volume of blood loss at delivery, umbilical cord venous pH, Apgar 
scores at 1 and 5 minutes and whether or not the infent required admission to the neonatal unit. In 
those patients in whom an adverse outcome was seen, the patient notes were examined by an 
independent observer (the academic supervisor. Dr Jane Norman) to ensure that the adverse effect 
was not attributable to the intra-vaginal administration of IMN.
Comparisons were made between the three treatment groups. Statistical analysis of the numerical data 
was performed by analysis of variance using a general linear model of repeated measures (SPSS fo r  
Windows, Version 8). Significant differences in symptoms between the groups were determined by the
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Chi squared test. A p value of less than 0.05 was regarded as statistically significant. It was 
calculated that a study of 36 patients would have an 80 % power to detect the following differences 
between each of the IMN groups and the control group at the 5% significance level; maternal pulse 
16 beats per minute, systolic blood pressure 12 mmHg, diastolic blood pressure 8mmHg, fetal heart 
rate 13 beats per minute, umbilical artery RI 10%, umbilical artery PI 15% and cord pH 0.11.
Results:
38 women were recruited to the study. 2 women were excluded from the study after they had been 
allocated a treatment, but before its administration. One of these women was excluded because of an 
undiagnosed breech presentation and the other because treatment administration was delayed, and in 
the interval, spontaneous labour ensued. These women were therefore excluded from the analysis.
Patient characteristics, maternal and neonatal outcomes are shown in Table 1. 13 women received 20 
milligrams IMN. These women had a median age of 26 years (range 19-36 years) and a median 
gestation of term + 9 days (range term + 3 - term + 1 1  days). 11 women received 40 milligrams 
IMN. These women had a median age of 27 years (range 1 7 -3 4  years) and a median gestation of 
term + 9 days (range term + 6 - terra + 10 days). 12 women received a vaginal examination only. 
These women had a median age of 28 years (range 16-38 years) and a median gestation of term + 9 
days (range term + 7 - term + 1 1  days). The indication for induction of labour (as defined by the 
obstetrician caring for the woman) was post dates pregnancy in all women.
Mean maternal pulse was higher following the administration of 20 and 40 milligrams IMN 
compared to the control group (p = 0.003 and p = 0.01 respectively) (Figure 1). The greatest 
difference in mean maternal pulse rate between either o f the IMN groups and the control group was at 
300 minutes, with a difference in mean maternal pulse of 21 beats per minute (95% Cl 5 - 37 beats 
per minute) between the 20 milligrams IMN and the control group. There was no significant 
difference in maternal pulse rate between the IMN groups.
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Both 20 and 40 milligrams IMN were associated with lower mean maternal blood pressures compared 
to the control group (Figure II). The intra-vaginal administration of 40 milligrams IMN was 
associated with a reduction in maternal systolic blood pressure compared to no treatment (p = 0.006). 
The difference in mean maternal systolic blood pressure between the 40 milligrams IMN and the 
control group was greatest at 300 minutes (greatest difference = 1 5  mmHg, 95% Cl 2 - 26 mmHg). 
There was no significant difference in mean maternal systolic blood pressure between the 20 
milligrams IMN group when compared with both the 40 milligrams IMN group and the control 
group.
Both 20 and 40 milligrams IMN were associated with a fall in maternal diastolic blood pressure 
compared to no treatment (p = 0.01 and p = 0.001 respectively). The greatest difference in mean 
maternal diastolic blood pressure occurred between the 40 milligrams IMN and the control group 
(greatest difference = 1 6  mmHg, 95% Cl 7 - 24 mmHg). Mean maternal diastolic blood pressure was 
significantly lower following the administration of 40 milligrams IMN compared to the 
administration of 20 milligrams (p = 0.01). During the study none of the women experienced any 
symptoms of h>^otension or required treatment for hypotension.
There was no statistically significant difference in fetal heart rate following the administration of 20 
and 40 milligrams IMN compared to the group that received no treatment. There was also no 
statistically significant difference in fetal heart rate between the IMN groups (Figure III). There was 
no evidence of fetal compromise on cardiotocograph monitoring during the study. Neither dose of 
IMN had a statistically significant effect on umbilical artery Doppler indices (Table 11).
The most frequent maternal side effect associated with IMN was headache, which occurred in 69% 
(9/13) of women who received 20 milligrams IMN and 91% (10/11) of women who received 40 
milligrams IMN, compared with only 8% (1/12) women in the control group (p=0.001). There were 
no other statistically significant differences in reported symptoms (abdominal pain, pelvic pain, hot 
flushes, faintness, drowsiness, tiredness, heartburn, nausea and vomiting) (Figure IV). During the 
study none of the women reported any of the following symptoms; constipation, diarrhoea, loss of 
appetite, bloating, breast tenderness, dysuria or change in fetal movements.
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The women that received 40 milligrams IMN had higher mean cervical scores at 360 minutes 
compared to those women that had received 20 milligrams IMN or no treatment, but these differences 
in cervical score did not reach statistical significance. More women in the control group required 
further cervical priming in the form of prostaglandin E2 compared to both IMN groups. Again these 
differences were not statistically significant. There were also no statistically significant differences in 
the number of women in each group that required intravenous oxytocin during labour induction, 
although fewer women in the control group required oxytocin (Table I).
There were no statistically significant differences in the length of labour for those women who had a 
spontaneous vaginal delivery, mode of delivery, analgesia use during labour, volume of blood loss 
following delivery, umbilical venous cord pH, Apgar scores at 1 minute and 5 minutes or the rates of 
admission to the neonatal unit (Table I).
59
Figure 1 - Mean maternal pulse rate at baseline and at 30 minute intervals 
following the intra-vaginal administration of 20 mg IMN, 40 mg IMN and 
no treatment (control group):
Maternal Pulse 
(bpm) (95 % Cl) IMN 20mg -O — IMN 40mg —A— Control
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Figure II - Mean maternal systolic and diastolic blood pressure at baseline 
and at 30 minute intervals following the intra-vaginal administration of 
20 mg IMN, 40 mg IMN and no treatment (control group):
Blood Pressure 
(mmHg) (95 % Cl) IMN20 mg — I MN 40mg —A— Control
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Figure III - Mean fetal heart rate per minute at baseline and at 30 minute 
intervals following the intra-vaginal administration of 20mg IMN, 40mg 
IMN and no treatment (control group):
Fetal Heart Rate 
(bpm) (95 %CI)
IMN 20mg - Q -  IMN 40mg Control
160 1
140
120
600 90 120 150 180 210 240 270 300 330 36030
Time (minutes)
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Figure IV - Maternai symptoms at 360 minutes following the intra- 
vaginal administration of 20 milligrams IMN, 40 milligrams IMN and no 
treatment (control group):
■ IMN 20 Milligrams □ IMN 40 Milligrams □ Control Group
80
60
40
20 it
Headache AbdominalPelvic Pain Hot Faintness Drowsiness Tiredness Indigestion Vomiting 
Pain Flushes
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Table I - Description of Patients / Maternal and Neonatal Outcomes:
IMN 20 
(n=13)
IMN 40 
(n = ll)
Control
(n=12)
26 27 28
Median Age (Years)
(19 -36) (17 - 34) (16 -38)
289 289 289
Median Gestation (Days)
(283 - 289) (286 - 290) (287 - 291)
4 4 4
Median Cervical Score 0 Min
(2 -6 ) (1 -6 ) (2 -6 )
4 6 5
Median Cervical score 360 Min
(2 -8 ) (3 -9 ) (2 -9 )
Number Requiring Prostaglandin 9 (69%) 7 (64%) 10 (84%)
Number Requiring Oxytocin 11 (85%) 11 (100%) 9 (75%)
Median Induction to Delivery 1628 1760 1623
Interval (Min)* (615-2142) (1062 - 2075) (1060 - 2394)
315 370 390
Median Length Stage I (Min)*
(30 - 865) (115 - 550) (250 - 895)
48 92 109
Median Length Stage II (Min)*
(5 - 172) (32 - 173) (4 -1 3 9 )
7 9 7
Median Length Stage III (Min)*
(2 -1 9 ) (2 -2 5 ) (3 - 16)
No statistically significant differences between the groups. 
* Women delivered by LUSCS excluded.
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Table I (continued) - Description of Patients / Maternal and Neonatal Outcomes:
IMN 20 
(n=13)
IMN 40 
(n = ll)
Control
(n=12)
SVD 4(31% ) 5 (45%) 5 (42%)
Forceps / Ventouse 3 (23%) 4 (36%) 3 (25%)
LUSCS 6 (46%) 2(18% ) 4 (33%)
IM Opiate 11 (85%) 11 (100%) 6 (50%)
Epidural 10 (77%) 11 (100%) 11 (92%)
Median Estimated Blood Loss (ml)
400 
(100 - 1000)
300 
(100 - 2500)
300 
(100 - 1250)
Median Umbilical cord pH
7.33 
(7.03 - 7.39)
7.27
(7.19-7.36)
7.32
(7.16-7.37)
Median Apgar 1 Minute
9
(3 - 10)
9
(5 -9 )
9
(6 -1 0 )
Median Apgar 5 Minutes
9
(5 - 10)
9
(8 - 10)
10
(9 -1 0 )
SCBU Admissions 3 (23%) 2 (18%) 3 (25%)
No statistically significant differences between the groups.
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Table II - Median (+ range) Umbilical Artery Resistance Index (RI) and Pulsatility Index (PI) at 
0, 180 and 330 minutes following 20milligrams IMN, 40 milligrams IMN or no treatment 
f control! :
IMN 20 
(n=13)
IMN 40 
(n = ll)
Control
(n=12)
0.58 0.55 0.55
RI 0 min
(0.53 - 0.65) (0.46 - 0.64) (0.43-0.61)
0.57 0.51 0.58
RI 180 min
(0.48 - 0.65) (0.45 - 0.57) (0.5 - 0.62)
0.53 0.54 0.56
R I330 min
(0.45 - 0.65) (0.42 - 0.59) (0.49 - 0.62)
0.89 0.81 0.78
PI 0 min
(0.75 - 1.1) (0.64 - 0.99) 0.56 - 0.94)
0.83 0.71 0.87
PI 180 min
(0.66 - 1.07) (0.61 - 0.84) (0.68 - 0.98)
0.76 0.79 0.85
PI 330 min
(0.59- 1.07) (0.57 - 0.95) (0.68 - 0.99)
No statistically significant differences between the groups.
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Discussion:
NO donors are a class of drugs that act by liberating NO in vivo. They include isosorbide mononitrate 
(IMN) isosorbide dinitrate (IDN), sodium nitroprusside (SNP) and glyceryl trinitrate (GTN). The 
vasodilatory effects of NO donors are widely used in the treatment of ischaemic heart disease and 
cardiac failure. The adverse effects of these agents are mainly secondary to vascular smooth muscle 
relaxation and include hypotension, tachycardia and headache.
It has been suggested that the intra-vaginal administration of an NO donor might be considered as an 
alternative to agents that are currently used to induce cervical ripening during the induction of labour 
at term ®. The relaxation effects of an NO donor in the myometrium and in the utero-placental 
circulation could provide advantages over other agents that are currently being used to induce cervical 
ripening. Conversely any hypotensive effects caused by an NO donor would be unwanted. 
Furthermore, profound maternal hypotension may compromise uterine blood flow and adversely 
affect fetal well-being.
When this study was designed there were no published studies regarding the use of intra-vaginal IMN 
administered to pregnant women at term to induce cervical ripening. In designing this study it was 
felt that systemic absorption would be minimal and that the maximal effects of the drug would be 
confined to the site of administration, i.e. the cervix. Our experience of using NO donors in pregnant 
women at term is limited, and it was therefore felt that a study of the potential adverse effects of such 
agents should be undertaken, prior to any larger study concerning the eflScacy of IMN in inducing 
cervical ripening in pregnant women at term. As discussed the principal adverse effects of NO donors 
are related to changes in the vascular system. In theory NO donors such as IMN will cross the 
placenta and therefore the intra-vaginal administration of IMN could also have effects on the fetal 
haemodynamics.
In this study the administration of a single dose of 20 and 40 milligrams intra-vaginal IMN had a 
small, but statistically significant effect on maternal haemodynamics. Both 20 and 40 milligrams of 
IMN caused a rise in mean maternal heart rate and a fall in mean maternal diastolic blood pressure.
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The intra-vaginal administration o f 40 milligrams IMN was associated with a reduction in mean 
maternal systolic blood pressure and also produced a greater reduction in mean maternal diastolic 
blood pressure compared to the intra-vaginal administration of 20 milligrams IMN. There was a 
maximal increase in mean maternal pulse rate of 21 beats per minute and a maximal fall in mean 
maternal systolic and diastolic blood pressure of 15 mmHg and 16 mmHg respectively. During the 
study there were no episodes of symptomatic hypotension, nor did any woman require treatment 
because of these observed changes in blood pressure.
Although there are no published studies regarding the use of intra-vaginal IMN administered to 
pregnant women at term Thomson et al have examined mean maternal blood pressure following the 
intra-vaginal administration of 40 milligrams IMN to women in the first trimester undergoing 
surgical termination of pregnancy In contrast to the results observed in this study no significant 
effects were observed in women in the first trimester following the intra-vaginal administration of 40 
milligrams IMN. The most likely reason for this discrepancy is that the fiequent blood pressure 
measurements performed in the study reported here may reveal subtle fluctuations in mean maternal 
systolic and diastolic blood pressure that were not apparent when blood pressure was measured on 
only two occasions during the study of Thomson et al. Alternative explanations include differences in 
cervical composition between the first and third trimesters of pregnancy resulting in altered 
pharmacokinetics of vaginally administered IMN, and also the differences in the maternal circulation 
that exist between the first and third trimesters of pregnancy.
During pregnancy NO donors other than IMN have been administered for a number of indications via 
the intravenous, transdermal or sublingual route. The intravenous infusion o f GTN to pregnant 
women in the third trimester of pregnancy with severe preeclampsia is associated with a small rise in 
mean maternal heart rate and a reduction in both mean maternal systolic and diastolic blood pressure 
The use of intravenous GTN in the treatment of intra-partum fetal distress caused by uterine 
hyperstimulation is associated with hypotension that requires treatment in 25% of cases
Several authors have reported the use of transdermal GTN in the treatment of pre-term labour and in 
the prophylaxis of preeclampsia and have concluded that transdermal GTN does not appear to be
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associated with maternal hypotension nor tachycardia A  rate of maternal tachycardia of
only 2% is seen following the administration of 10 to 20 milligrams transdermal GTN to women in 
the treatment of pre-term labour
Nevertheless there are studies that suggest that the administration of transdermal GTN is associated 
with maternal haemodynamic changes. Bisits et al reported that the administration of 10 milligrams 
GTN transdermally in the treatment of pre-term labour was associated with no changes in maternal 
heart rate, but was associated with a small but clinically insignificant fall in maternal systolic blood 
pressure The application of a 10 milligram GTN patch to women with pregnancies complicated 
by preeclampsia and intra-uterine growth restriction between 28 and 36 weeks gestation is not 
associated with any changes in mean maternal heart rate, but is associated with a reduction in mean 
maternal arterial pressure The fall in mean maternal arterial pressure caused by the
administration of transdermal GTN is due to a reduction in systolic blood pressure
The sublingual administration of 5 milligrams isosorbide dinitrate (IDN) in the first and second 
trimesters of pregnancy is associated with a small increase in mean maternal heart rate and a small 
reduction in mean maternal arterial pressure Despite these changes in maternal
haemodynamics following the transdermal and sublingual administration of an NO donor to pregnant 
women, treatment for hypotension is rarely required.
This study is the first to determine maternal pulse and blood pressure changes following the intra- 
vaginal administration of IMN to pregnant women at term. It suggests that the intra-vaginal 
administration of IMN in the late third trimester of pregnancy has no clinically significant adverse 
effects on maternal haemodyamics. The small effect of IMN in stimulating maternal pulse rate and 
depressing maternal blood pressure is not sufficient to preclude the consideration of intra-vaginal 
IMN as a cervical ripening agent for healthy pregnant women at term. The stimulatory effect of IMN 
on maternal heart rate may however prevent the use of IMN in women with some cardiac conditions 
such as dysrhythmias and hypertrophic obstructive cardiomyopathy, although these conditions are 
rarely seen in pregnant women at term.
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Despite evidence of effects on maternal pulse and blood pressure there were no statistically significant 
changes in fetal heart rate following the intra-vaginal administration of both 20 and 40 milligrams 
IMN. During this study there were also no cardiotocograph abnormalities that suggested fetal 
compromise after the intra-vaginal administration of IMN. These findings are consistent with 
previous studies in which an NO donor has been administered to women in the third trimester of 
pregnancy The intra-venous administration of 0.25-10.0 micrograms/kilogram GTN
and the transdermal administration of 10 milligrams GTN to pregnant women in the third trimester 
of pregnancy have no effect on fetal heart rate
Doppler ultrasound is used to assess blood flow of the uterine, placental and fetal circulation. The 
resistance and pulsatility indexes (RI and PI) provide a measure of resistance to flow. In this study 
the intra-vaginal administration of 20 and 40 milligrams of IMN had no effect on umbilical artery RI 
and PI at 180 and 360 minutes after treatment. This finding is again consistent with previous 
observations following the administration of an NO donor to women in the third trimester of 
pregnancy. The administration of transdermal GTN for the treatment of pre-term labour has no effect 
on umbilical artery Doppler indices The administration of transdermal GTN to women in the 
third trimester of pregnancies complicated by preeclampsia and intrauterine growth restriction had no 
effect on umbilical artery RI and PI .
There is however a significant fall in maternal uterine artery RI and PI following the administration 
of transdermal GTN to pregnant women between 28 and 36 weeks gestation with pregnancies 
complicated by preeclampsia The intravenous infiision of GTN reduces maternal uterine artery 
RI and PI in women in the first trimester of pregnancy undergoing termination of pregnancy, and also 
in women between 24 and 26 weeks gestation with reduced placental blood fiow^^ .^ However in 
women between 24 and 26 weeks gestation the intravenous infusion of GTN produced no statistically 
significant changes in umbilical and middle cerebral artery RI and PI These observations suggest 
that the administration of NO donors to pregnant women in the third trimester of pregnancy is less 
likely to affect fetal haemodynamics.
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In humans the sublingual administration of the NO donor IDN is associated with a reduction in 
umbilical artery RI and PI in women in the first and second trimesters of pregnancy The
intravenous infusion of GTN in the third trimester o f pregnancies complicated by severe preeclampsia 
is also associated with a reduction in umbilical artery PI during the time of infusion The increase 
in umbilical artery flow that has been demonstrated in these studies might be attributable to a direct 
effect of NO donors that have crossed the placenta. Alternatively, it may be that these umbilical 
artery responses are merely reactions to the increase in uterine perfusion caused by changes in the 
maternal systemic circulation in response to the administration of an NO donor.
It may be NO donors have some transient effects on fetal haemodynamics that are short lasting and 
this may explain why no changes in umbilical artery RI and PI were demonstrated in the study 
presented in this thesis and other studies. The changes in umbilical artery Doppler indices that were 
seen following the sublingual administration of IDN to pregnant women in the first and second 
trimesters occurred within 20 minutes In the study presented in this thesis the decision to
record Doppler indices at 180 and 330 minutes following treatment administration was based on the 
availability of the ultrasound fecilities within the unit. It may be that by limiting the recordings to 
these times transient changes in fetal haemodynamics were missed.
However Bisits et al have demonstrated that the transdermal administration of GTN to pregnant 
women in the third trimester of pregnancy has no effect on umbilical and fetal arterial Doppler 
parameters at 30 minutes following the administration of the NO donor The differences in the 
effects of NO donors on umbilical Doppler indices may be the result of pharmacokinetic differences 
between the different preparations of NO donor and the different routes of administration.
In this study the main symptom reported by women following the intra-vaginal administration of 20 
and 40 milligrams of IMN was headache, with fi-equencies (69 and 91%) that were significantly 
greater than in the control group (8%). Headache is a recognised side effect of NO donors. Following 
the intra-vaginal administration of 40 milligrams IMN in the first trimester of pregnancy headache 
was reported in 23% of cases There are a number of possible explanations for the differences in the 
frequency of headache in this study and that of Thomson et aF. Again the differences may be
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explained by altered pharmacokinetics secondary to changes in cervical composition and maternal 
cardiovascular changes during the third trimester of pregnancy. However in the study performed by 
Thomson et al the symptom questionnaire was completed at 180 minutes and it may be that if  given 
more time, more women may have reported the symptom of headache.
In studies where the transdermal GTN has been administered to pregnant women for the treatment of 
pre-term labour, headache is one of the most frequently reported symptoms. In these studies the 
reported rates of headache are 30% 31% 33% 64% 100% Headache has
also been reported following the intravenous infusion of GTN with reported rates varying from 12.5 
to65%^^ '^^ t^
The intra-vaginal administration of 40 milligrams IMN caused a slight increase in cervical score 
compared to those groups that received 20 milligrams IMN and no treatment. Furthermore fewer 
women that received 20 and 40 milligrams IMN required prostaglandin Eg for further cervical 
ripening compared to the group that received no treatment. These findings while not statistically 
significant, would suggest that intra-vaginal IMN might have a role to play in the pharmacological 
induction of cervical ripening.
The intra-vaginal administration of 20 and 40 milligrams IMN had no statistically significant effects 
on the subsequent course of labour and delivery, including length of labour, analgesic use during 
labour, operative delivery rates, blood loss at the time of delivery and neonatal outcomes. More 
women required oxytocin in the groups that received 20 and 40 milligrams IMN, and in these women 
the induction of labour to delivery interval was longer than in the group that received no treatment. 
These findings are perhaps a reflection of the relaxing effects that NO donors have on the 
myometrium.
There has only been one other study published in which an intra-vaginal NO donor has been 
administered to pregnant women at term for the induction of cervical ripening In this study 
pregnant women at term were randomised to receive 2 intra-vaginal doses of 500 micrograms GTN at 
6 hourly intervals, or 2 intra-vaginal doses of 3 milligrams prostaglandin E^. Following the intra-
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vaginal administration of GTN there were fewer episodes of uterine hyperstimulation and the median 
Bishop Score at 12 hours was greater compared to the group that had received intra-vaginal 
prostaglandin E2. Consistent with the results presented in this thesis, oxytocin requirements were less 
in the group that had received intra-vaginal PGE2, and these women also had significantly shorter 
labours compared to the group that had received intra-vaginal GTN. There were no differences in 
operative delivery rates between the group that had received intra-vaginal GTN and the group that 
had received intra-vaginal PGE2.
Chanrachakul et al also made some assessment of maternal and fetal haemodynamics following the 
intra-vaginal administration of GTN Following the intra-vaginal administration of GTN there 
were no significant changes in maternal heart rate, maternal blood pressure and fetal heart rate 
However maternal haemodynamic parameters were only assessed at 4 hourly intervals and fetal heart 
rate was not recorded continuously unless an abnormality was detected.
Headache was seen in only 9% of cases following the intra-vaginal administration of GTN^^^. There 
are a number of reasons to explain the differences in the rates of headache following the intra-vaginal 
administration of GTN and the study presented in this thesis. The differences may be due to 
differences in pharmacokinetics between intra-vaginal GTN and intra-vaginal IMN. On the other 
hand following the intra-vaginal administration of GTN patients were only asked to report symptoms 
when they were present, and no objective symptom questionnaire was completed. Therefore the true 
incidence of headache following the intra-vaginal administration of GTN may in fact be higher than 
that reported by Chanrachakul et al
The intra-vaginal administration of GTN is also effective at inducing cervical ripening in the first 
trimester of pregnancy However in the first trimester of pregnancy GTN is not as effective as IMN 
at lowering cervical resistance^. It therefore follows that if  intra-vaginal GTN is effective at inducing 
cervical ripening in pregnant women at term, IMN is also likely to be effective. A randomised trial of 
intra-vaginal IMN versus both placebo and the current agent of choice, prostaglandin E2, is required 
to assess the efficacy of IMN as a cervical ripening agent and its adverse effects. Subsequently the 
intra-vaginal administration of IMN to pregnant women at term could be compared with other agents
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that are used to induce cervical ripening such as mechanical devices, misoprostol and mifepristone. 
A power calculation indicates that a study with over 100 women in each arm will be required to 
determine whether or not IMN is an effective cervical ripening agent in the third trimester o f human 
pregnancy.
Another area of future research is to determine which NO donor is the most appropriate for the 
induction of cervical ripening in pregnant women at term. A recently published study has shown that 
intra-cervical administration of 5 and 10 milligrams o f the NO donor SNP is effective at inducing 
cervical ripening in the first trimester prior to termination of pregnancy In the first trimester of 
pregnancy the intra-cervical administration of 5 and 10 milligrams of SNP is not associated with any 
adverse effect on maternal blood pressure or maternal headache The efficacy SNP in the 
induction o f cervical ripening in pregnant women at term has yet to be determined. With its low 
incidence of headache, intra-cervical SNP may be a more acceptable agent than intra-vaginal IMN in 
the induction of cervical ripening in pregnant women at term. Therefore a randomised controlled 
trial of intra-vaginal IMN versus other NO donors that are used to induce cervical ripening, such as 
intra-vaginal GTN and intra-cervical/vaginal SNP, should be conducted in pregnant women at term 
to determine which NO donor is the most effective with the lowest incidence of adverse effects.
One of the difficulties encountered in the study presented in this thesis was in the recruitment of 
patients. More than a hundred women were approached during the study period. Most women 
declined to participate stating that they were unwilling to participate in a study that involved the 
administration of a drug that had never before been given to pregnant women at term. Patients were 
also concerned that the intra-vaginal administration of IMN may in fact prolong the induction 
process, because of the relaxing effects that IMN has on the uterus. Now that this study has been 
completed there is more information that can be given to those pregnant women at term who are 
considering participating in a study in which intra-vaginal IMN is being administered, thereby 
facilitating recruitment. Recruitment to any future study on the efficacy of IMN could also be 
improved by conducting a multi-centre study, allov^ng more patients the opportunity to participate.
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IV. Conclusion:
During pregnancy there are profound changes in the composition of the cervix that facilitate the 
process of cervical ripening. The mechanisms that regulate cervical ripening are incompletely 
understood. Our understanding of the physiological process of cervical ripening, and hence 
parturition, has allowed us to develop agents for the pharmacological induction of cervical ripening. 
Mechanical devices, oestrogen, relaxin, progesterone antagonists and prostaglandins have been used 
to induce cervical ripening in pregnant women at term. In the United Kingdom the current agent of 
choice is prostaglandin E2 gel. Prostaglandin gel is not without adverse effects, principally uterine 
hyperstimulation and subsequent fetal compromise. In view of these adverse effects the search for an 
alternative agent for the induction of cervical ripening in pregnant women at term continues.
The intra-vaginal administration o f an NO donor such as IMN has been proposed as an alternative to 
prostaglandin E2 gel for the induction of cervical ripening in pregnant women at term. The study that 
is presented in this thesis is the first to report the intra-vaginal administration IMN to pregnant 
women at term. NO donors could theoretically induce both maternal and fetal haemodynamic 
changes. It was therefore felt that it was important to address this issue before any study was 
undertaken examining the efficacy of IMN as a cervical ripening agent in pregnant women at term.
The intra-vaginal administration of 20 and 40 milligrams IMN during the induction of labour in the 
third trimester of pregnancy causes a small but statistically significant rise in maternal heart rate and 
a small reduction in maternal blood pressure. Furthermore the intra-vaginal administration of 20 and 
40 milligrams IMN had no significant effect on fetal heart rate or on umbilical artery Doppler 
indices, suggesting that intra-vaginal IMN has no effects on fetal haemodynamics. There were no 
clinically significant differences in maternal and fetal haemodynamics following the intra-vaginal 
administration of 20 and 40 milligrams IMN. The only statistically significant haemodynamic 
difference that was demonstrated was a lower mean maternal diastolic blood pressure and a higher 
incidence of headache following the intra-vaginal administration of 40 milligrams IMN. The only 
significant symptomatic maternal adverse effect was headache. It is perhaps a cause for concern that 
this was seen in over 90% of patients following the intra-vaginal administration of 40 milligrams
75
IMN. Nevertheless, the study presented in this thesis suggests that a dose of 40 milligrams is more 
effective than a dose of 20 milligrams IMN without any significant increase in adverse maternal or 
fetal adverse effects, other than maternal headache. Future studies on the efficacy o f IMN as a 
cervical ripening agent in pregnant women at term should therefore concentrate on using a dose of 40 
milligrams.
The ideal agent for the pharmacological induction of cervical ripening should be easy to administer, 
cost effective, acceptable to both patient and clinician and produce adequate cervical change with 
minimal maternal and fetal adverse effects. The vaginal administration of 40 milligrams IMN 
appears to fit these criteria. Intra-vaginal IMN is easy to administer, inexpensive, and has no 
clinically significant effects on maternal and fetal haemodynamics, I believe that the work presented 
in this thesis lays the foundation for future studies examining the efficacy of 40 milligrams IMN as a 
cervical ripening agent during the induction of labour.
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PATIENT INFORMATION SHEET AND CONSENT FORM
Are nitric oxide donors effective in inducing cervical ripening during the induction of labour at
term?
You have been admitted to hospital to have your labour induced (started off). This is normally done 
using a drug called prostaglandin. Prostaglandins ripen (start to open) the cervix (neck of the womb), and 
also stimulate the womb to contract. Although prostaglandins are effective in inducing labour, they are 
sometimes associated with side effects such as painful contractions before labour starts, or with an 
abnormal fetal heart rate pattern.
We are keen to investigate another drug called isosorbide mononitrate. This drug has been used for many 
years in people with heart disease. We have found that it also ripens the cervix. In early pregnancy, 
isosorbide mononitrate ripens the cervix with fewer side effects than prostaglandin. We wish to test 
whether this also happens at the end of pregnancy.
We should like to invite you to take part in a study comparing isosorbide mononitrate with no treatment 
to find out whether isosorbide mononitrate causes cervical ripening at the end of pregnancy. If you agree 
to take part in the study, you will receive either isosorbide mononitrate (given vaginaily), or no treatment 
(internal examination only). Over the next six hours, your blood pressure will be measured and we will 
record the baby’s heart rate. We will also scan the baby to see if there is any change in blood flow to the 
baby (in early pregnancy, drugs like isosorbide mononitrate improve the blood flow to the baby). At the 
end of six hours, your labour wiU be induced in the usual manner. We hope that by using isosorbide 
mononitrate the induction of labour will be easier.
You should be aware that the side effects which can be caused by isosorbide mononitrate are a headache 
and a drop in blood pressure for a short while.
Please note that if you agree to take part, this Research Project may be of little benefit to you but the 
results may help other patients in the future. If you do not want to take part in the Research Project, or 
if at any time you wish to stop taking part you may do so. The care which you are presently receiving 
will not be affected in any way. If you do agree to take part in the Research Project, your own general 
practitioner will be told and will be given details of information about any care which you are to receive.
CONSENT
I (name)..............................................................................................................
of (address)........................................................................................................
agree to take part in the Research Project described above.
Dr.................................... has explained to me what I have to do, how it might affect me and the purpose
of the Research Project.
Signed..................................................................Date......................................
Witness............................................  ....Date...................... ...............
Symptom questionnaire
The purpose of this questionnaire is to find out if the tablets we are going to give you make you feel 
unwell. We will ask you to complete this questionnaire immediately before the tablets are given, and then 
six hours later. If there is anything you do not understand, please ask.
Please tick the correct answer:
At this moment in time, are you suffering from any of the following:
headache: y e s n n o Q
drowsiness y e sD n o Q
nausea (sickness) y e sD n o D
indigestion y e sQ n o D
abdominal pain
(pain in the upper tummy)
y e sD n o D
pelvic pain
(pain in the lower tummy)
y e sD n o d
bloating y e sQ n o d
loss of appetite y e sQ n o d
diarrhoea y e sQ n o d
constipation y e sQ n o d
breast pain y e sQ n o d
weakness y e s n n o d
faintness y e sQ n o d
tiredness y e sQ n o d
hot flushes y e sQ n o d
In the last six hours, have you, had any of the following;
vomiting y e sQ n o d
pain passing urine y e sD n o d
